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ABSTRACT
Background: Dementia is characterized not only by cognitive and functional
decline, but also by neuropsychiatric symptoms (NPSs). These affect almost
all people with dementia during the course of the disease. NPSs are associated
with impaired health-related quality of life (HRQoL) and admission to long-
term care. People with dementia have an elevated risk of falling. Fall risk has
been associated with impaired mobility, some NPSs such as depression and
anxiety, and the use of psychotropic drugs. In long-term-care settings the
prevalence of use of any psychotropic drug has been reported to be very high.
There is a scarcity of studies on the interplay between NPSs, psychotropics,
falls, and HRQoL
Objectives: This study, comprised of four sub-studies, was aimed at
examining the relationships between NPSs, falls, psychotropic drug use and
HRQoL among people with dementia. The relationship between NPSs and falls
was explored in two different populations: home-dwelling older adults with
Alzheimer’s disease (AD) (Study I), and institutionalized older adults with
cognitive impairment (Study IV). Study I concerned how long-term exercise
modifies the risk of falling in community-dwelling people with AD and NPSs.
Study IV was carried out to explore whether or not psychotropic drug use
modifies the relationship between NPSs and falls. Study III concerned the
association between NPSs and HRQoL, and, further, how the severity of
dementia modifies this relationship. In addition, Study II concerned temporal
trends in the prevalence of use of psychotropics and opioids, and sedative load
in long-term-care settings over a 14-year period in relation to the residents’
dementia status.
Participants: Study I was a secondary analysis of a randomized controlled
trial, FINALEX. All the participants from the original FINALEX trial whose
spousal caregivers had completed the Neuropsychiatric Inventory (NPI) at
baseline and who had had at least three months of follow-up were included in
this study (n=179). Study II is based on Helsinki Nutrition and Medication
studies conducted in 2003–2018. It comprised four cross-sectional studies in
institutional settings in Helsinki. The participants were residents in nursing
homes (NHs) in 2003 (n=1987), 2011 (n=1576), and 2017 (n=791) and in
assisted-living facilities (ALFs) in 2007 (n=1377), 2011 (n=1586), and 2017
(n=1752). The participants of Studies III and IV were a random sample of long-
term-care residents aged 65 years and older in Helsinki (n=532).
Measures: NPSs were measured with the NPI. In Studies III and IV
participants were placed in three groups: no significant NPSs (NPI points 0–
3), low-NPS burden (4–12 points) and high-NPS burden (NPI >12 points). The
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severity of dementia was measured by using Clinical Dementia Rating (CDR).
HRQoL was measured by using the 15D instrument. Falls were recorded in
daily-falls diaries in Study I and collected from medical records in Study IV
over a one-year period. Data on demographics, diagnoses and medication were
collected from medical records. Types of medication were classified according
to Anatomical Therapeutic Chemical (ATC) classification.
Results: Mean ages ranged from 78 to 84 years in four large samples. The
participants had a high number of comorbidities and were given a high
number of drugs (mean range 6.9-8.6). The severity of cognitive impairment
varied. Most of the participants in Study I had mild to moderate dementia
(CDR 0.5–2), whereas almost all long-term-care residents had moderate to
severe dementia (CDR 2–3) (Studies II–IV).
In Studies I and IV falls had a clear relationship with NPSs measured by the
total NPI score. In Study I the incidence of falls increased linearly with NPI
score in the control group. The fall rate was 2.87 per person-years (95% Cl
2.43–3.35) in the control group, whereas the exercise intervention group
showed no such relationship with NPI score and had a fall rate of 1.48 per
person-years (95% Cl 1.26–1.73). In Study IV the NPI total score had a
curvilinear association with the incidence rate of falls per person-years. Using
the no-significant-NPSs group as a reference, the low-NPS-burden group had
an IRR per SD for falls of 1.64 (95% Cl 1.27–2.12), whereas in the high-NPS-
burden group the IRR per SD was 2.43 (95% Cl 1.91–3.08). Psychotropics did
not modify the relationship between NPSs and falls. Psychosis and
hyperactivity subsyndromes were associated with higher IRRs of falls, whereas
apathy and affective symptoms were not.
In Study III the severity of NPSs was significantly associated with better
HRQoL (15D measures). This seemed to be related to better physical
functioning and greater vitality. Residents with severe dementia (CDR 3) had
worse HRQoL than residents with mild-to-moderate dementia (CDR <3).
There was a significant interaction between NPI and CDR scores (p=0.037 for
NPI, p<0.001 for CDR and p<0.001 for interaction).
In Study II the prevalence of use of all psychotropics decreased significantly in
NHs (from 81% to 61%), whereas in ALFs there was no such trend (from 65%
to 64%). There was a significant increase in opioid use in both settings.
Residents with dementia used fewer psychotropics and opioids than those
without dementia in both settings and at all time points.
12
Conclusions: Neuropsychiatric symptoms and their severity are associated
with fall risk. Evaluation of NPSs, especially NPS severity and
neuropsychiatric subsyndromes, should be part of comprehensive assessment
when aiming to prevent falls in long-term-care residents with cognitive
impairment. Exercise has the potential to reduce the risk of falls associated
with NPSs. The severity of NPSs and dementia are both important factors
determining HRQoL. NPSs have a distinct impact on HRQoL at different
stages of dementia. The prevalence of psychotropic use has decreased over the
last 14 years in NHs in Helsinki, but at the same time the rates of opioid use
have increased in both NHs and ALFs, leading to a high overall sedative load
among long-term-care residents.
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TIIVISTELMÄ
Tutkimuksen tausta: Muistisairauksiin liittyy muistin ja toimintakyvyn
heikentymisen lisäksi neuropsykiatrisia oireita. Niitä esiintyy lähes kaikilla
muistisairauteen sairastuneilla jossakin vaiheessa sairautta.
Neuropsykiatriset oireet yhdistyvät heikompaan terveyteen liittyvään
elämänlaatuun ja lisääntyneeseen pitkäaikaishoidon tarpeeseen.
Muistisairausta sairastavilla on suurempi kaatumisriski kuin ei-
muistisairailla. Kaatumisriskiä lisäävät heikentynyt liikkumiskyky, eräät
neuropsykiatriset oireet kuten masennus ja ahdistuneisuus, sekä
psyykelääkkeiden käyttö. Pitkäaikaishoidossa psyykelääkkeiden käyttö on
erittäin yleistä. Tutkimusnäyttö muistisairauksien neuropsykiatristen
oireiden yhteyksistä psyykelääkkeiden käyttöön, kaatumisiin ja terveyteen
liittyvään elämänlaatuun on vähäistä.
Tutkimuksen tavoitteet: Tämän tutkimuksen tavoitteena oli tutkia
neuropsykiatristen oireiden yhteyksiä kaatumisiin, psyykelääkkeiden
käyttöön ja terveyteen liittyvään elämänlaatuun muistisairailla ihmisillä.
Tutkimus sisältää neljä osatyötä. Tutkimus selvitti neuropsykiatristen
oireiden yhteyksiä kaatumisiin kahdessa eri kohortissa: kotona asuvilla
Alzheimerin tautia sairastavilla ihmisillä (Osatyö I) sekä pitkäaikaishoidossa
asuvilla ihmisillä, joilla oli todettu muistin heikentymää (Osatyö IV). Osatyö I
tutki myös kuinka pitkäaikainen liikunta muokkaa kaatumisriskiä kotona
asuvilla Alzheimerin tautia sairastavilla ihmisillä, joilla on neuropsykiatrisia
oireita. Osatyö IV tutki muokkaako psyykelääkkeiden käyttö
neuropsykiatristen oireiden ja kaatumisten yhteyttä. Osatyö III tutki
neuropsykiatristen oireiden ja terveyteen liittyvän elämänlaadun yhteyttä ja
kuinka muistisairauden vaikeusaste on siihen yhteydessä. Lisäksi, osatyö II
tutki psyykelääkkeiden, opioidien ja sedatiivisen lääkekuorman muuttumista
pitkäaikaishoidossa 14 vuoden seuranta-ajalla muistisairailla ja ei-
muistisairailla.
Aineisto: Osatyö I oli alaryhmäanalyysi satunnaistetusta kontrolloidusta
tutkimuksesta FINALEX:sta. Tutkimukseen otettiin mukaan kaikki
tutkittavat, joiden puoliso oli täyttänyt NPI-mittarin (Neuropsychiatric
Inventory) ja joiden seuranta-aika oli ainakin 3 kuukautta (n=179). Osatyö II
perustuu Helsingin laitosvanhusten ravitsemus- ja lääketutkimukseen.
Tutkittavat koostuivat neljästä suuresta poikkileikkauskohortista. Tutkittavat
olivat asukkaita vanhainkodeissa vuosina 2003 (n=1987), 2011 (n=1576) ja
2017 (n=791) ja tehostetussa palveluasumisessa vuosina 2007 (n=1377),
(n=1586) ja 2017 (n=1752). Osatöiden III ja IV tutkittavat olivat satunnaisotos
kaikista yli 65 -vuotiaista pitkäaikaishoidon asukkaista Helsingissä (n=532).
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Menetelmät: Neuropsykiatrisia oireet selvitettiin NPI mittarilla. Osatöissä
III ja IV tutkittavat jaettiin kolmeen ryhmään neuropsykiatristen oireiden
vaikeusasteen perusteella: ei merkitseviä oireita (NPI 0-3), lievä oirekuva (NPI
4-12), voimakas oirekuva (>12). Muistisairauden vaikeusaste mitattiin CDR-
mittarilla (Clinical Dementia Rating). Terveyteen liittyvää elämänlaatua
mitattiin 15D mittarilla. Kaatumiset rekisteröitiin puolisoiden reaaliajassa
pitämiin kaatumispäiväkirjoihin osatyö I:ssä ja kerättiin
potilastietojärjestelmästä osatyö IV:ssa vuoden seuranta-aikana.
Demografiset tiedot, diagnoosit ja säännöllisesti käytössä oleva lääkitys
vahvistettiin sairaskertomustiedoista. Lääkkeet koodattiin käyttämällä
WHO:n ATC koodeja (Anatomical Therapeutic Chemical Classification).
Tulokset: Tutkittavien keski-ikä oli 78-84 vuotta neljässä eri kohortissa.
Tutkittavilla oli useita pitkäaikaissairauksia ja pysyviä lääkityksiä.
Säännöllisessä käytössä oli keskimäärin 6.9-8.6 lääkettä. Tutkittavien muistin
oli lievemmin heikentynyt osatyössä I (CDR 0.5-2), kun taas
pitkäaikaishoidossa lähes kaikilla oli vaikea-asteinen muistin heikentymä
(CDR 2-3) (osatyöt II-IV).
Sekä osatyössä I että IV, kaatumiset olivat yhteydessä neuropsykiatrisiin
oireisiin mitattuna NPI mittarilla. Osatyössä I kaatumisten määrä kasvoi
lineaarisesti NPI pisteiden kanssa kontrolliryhmässä. Kaatumisia oli 2.87
henkilövuotta kohden (95%:n luottamusväli 2.43-3.35). Interventioryhmässä
vastaavaa kasvua ei tapahtunut. Kaatumisia oli interventioryhmässä 1.48
henkilövuotta kohden (95%:n luottamusväli 1.26-1.73). Osatyössä IV
kaatumisten ilmaantuvuusriski oli kaareutuvasti (kurvilineaarisesti)
yhteydessä NPI pisteisiin. Kun ryhmää, jolla ei ollut merkitseviä
neuropsykiatrisia oireita käytettiin referenssinä, niin lievästi
neuropsykiatrisesti oireilevien kaatumisten ilmaantuvuusriski oli 1.64 (95%:n
luottamusväli 1.27-2.12) ja voimakkaasti oireilevien taas 2.43 (95%:n
luottamusväli 1.91-3.08). Psyykelääkkeiden käyttö ei muokannut
kaatumisriskin ja neuropsykiatristen oireiden välistä yhteyttä.
Neuropsykiatrisista oireryvästymistä psykoosi ja hyperaktiivisuus olivat
yhteydessä suurempaan kaatumisriskiin, kun taas apatia ja tunneoireet eivät
olleet.
Osatyössä III neuropsykiatristen oireiden voimakkuus oli merkitsevästi
yhteydessä parempaan terveyteen liittyvään elämänlaatuun mitattuna 15D
mittarilla. Tulos vaikutti olevan yhteydessä parempaan toimintakykyyn ja
energisyyteen. Tutkittavilla, joilla oli vaikea-asteiseksi edennyt muistisairaus
(CDR 3) oli huonompi elämänlaatu kuin, tutkittavilla, joiden muistisairaus oli
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lievempi (CDR<3). NPI:n ja CDR:n välillä oli merkitsevä interaktio (p=0.037
NPI, p<0.001 CDR, p<0.001 interaktio).
Osatyössä II kaikkien psyykelääkkeiden esiintyvyys väheni merkitsevästi
vanhainkodeissa (81-61%), kun taas tehostetussa palveluasumisessa ei
tapahtunut samanlaista muutosta (65-64%). Opioidien käyttö kasvoi
merkitsevästi molemmissa kohorteissa. Muistisairaat käyttivät vähemmän
psyykelääkkeitä ja opioideja verrattuna ei-muistisairaisiin molemmissa
kohorteissa.
Johtopäätökset: Neuropsykiatriset oireet ovat riskitekijä kaatumisille.
Kaatumisriski kasvaa neuropsykiatristen oireiden lisääntyessä.
Neuropsykiatristen oireiden arviointi tulisi ottaa osaksi kokonaisvaltaista
arviota, kun pitkäaikaishoidossa asuvien ihmisen kaatumisriskiä halutaan
pienentää. Liikuntaharjoittelu voi vähentää neuropsykiatrisiin oireisiin
yhdistyvää kaatumisriskiä. Sekä neuropsykiatristen oireiden että
muistisairauden vaikeusaste vaikuttaa terveyteen liittyvään elämänlaatuun.
Neuropsykiatristen oireiden ja terveyteen liittyvän elämänlaadun yhteys on
erilainen eri muistisairauden vaiheissa. Psyykelääkkeiden käytön esiintyvyys
on vähentynyt viimeisen 14 vuoden aikana vanhainkodeissa Helsingissä,
mutta samalla opioidien käyttö on lisääntynyt, johtaen siihen, että
keskushermostoon vaikuttavia väsyttäviä lääkkeitä käytetään yhä paljon
pitkäaikaishoidossa.
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INTRODUCTION
As the world’s population is aging at an increasing rate, the number of people
with dementia is growing. Every year, there are almost 10 million new cases
globally, one every three seconds. The total number of people with dementia
is predicted to reach 82 million in 2030 and 152 million in 2050 (WHO, 2019).
Cognitive decline is considered the hallmark of dementia, but
neuropsychiatric symptoms (NPSs) affect up to 97% of those diagnosed with
dementia during the course of their illness (Steinberg et al. 2008). Clinically
significant NPSs can result in various negative consequences, such as distress
and decreased quality of life in both caregivers and patients, increased
healthcare costs and early admission to long-term care (Beeri et al. 2002,
Wancata et al. 2003, Lethin et al. 2017). NPSs are also related to psychotropic
drug use (Selbæk et al. 2007, Wetzels et al. 2011) and lately its relationship
with other central nervous system (CNS) drugs such as opioids has been under
discussion (Brown et al. 2015, Kales et al. 2019).
People with dementia have a significantly higher risk of falling than those
without (van Doorn et al. 2003). The risk is twice as high in community-
dwelling people with dementia than in those without (Welmerink et al. 2010).
The risk factors of falls are multiple and vary between community- and
institution-dwelling older adults with dementia. Use of psychotropic drugs
and dementia have both been shown to increase fall risk (Allan et al. 2009,
Kröpelin et al. 2013, Fernando et al. 2017). In addition, there are some studies
suggesting that NPSs are associated with falls (Sylliaas et al. 2012).
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Earlier studies have thus shown that the prevalence of NPSs, falls and
psychotropic drug use is very common in dementia, especially among those in
long-term care (Rubenstein et al. 2006, Gulla et al. 2016). Less is known about
the interplay of these factors. Therefore, the focus of this thesis is to
understand the relationships between dementia, neuropsychiatric symptoms,
falls and psychotropic drug use, and how they affect quality of life.
18
REVIEW OF THE LITERATURE
2.1 NEUROPSYCHIATRIC SYMPTOMS (NPSs) IN
DEMENTIA
Dementia is characterized not only by cognitive and functional decline, but
also by symptoms that affect an individual`s personality, emotions, and
behavior (McKhann et al. 2011, Gitlin et al. 2012). These symptoms are called
neuropsychiatric symptoms (NPSs) or behavioral and psychological
symptoms of dementia (BPSD) (Finkel et al. 1996, Gilmore-Bykovskyi et al.
2019). In this thesis the term NPSs will be used. The impairment in cognitive
function is sometimes preceded by NPSs causing confusion in the patient or
his/her family long before dementia diagnosis is made (Taragano et al. 2009).
Additionally, NPSs can be the most significant challenge in dementia care, for
both clinicians and caregivers. Clinically significant NPSs may result in various
negative consequences, such as distress and decreased quality of life in both
caregivers and patients, early admission to long-term care, misuse of
medication, and increased healthcare costs (Beeri et al. 2002, Wancata et al.
2003, Kales et al. 2005, Lethin et al. 2017). A broader understanding of NPSs
is needed to improve their management.
2.1.1 EPIDEMIOLOGY OF NPSs
Almost all individuals with dementia experience at least one significant NPS
during the course of their disease (Steinberg et al. 2008, Savva et al. 2009,
Kales et al. 2015,) Sometimes it can be the first symptom of a neurocognitive
disorder (NCD), but NPSs are most common in moderate–severe dementia
(Cummings 1997, Zhao et al. 2016, Gallagher et al. 2017). A new term, “mild
behavioral impairment” (MBI) has been suggested to describe a potential
manifestation of prodromal dementia, similar to mild cognitive impairment
(MCI), in which the cognitive deficits do not interfere with the capacity for
19
independence in everyday life  (APA 2013, Ismail et al. 2016). MBI criteria
have been proposed by the International Society to Advance Alzheimer’s
Research and Treatment. These criteria include changes in behavior or
personality observed by the patient, informant, or clinician starting in later life
(age≥50 years) and persisting at least intermittently for a minimum of six
months.  According to Ismael et al. affective and emotional dysregulation are
common in preclinical dementia syndromes, often being predictors of
neurodegenerative change and progressive cognitive decline (Ismail et al.
2018).
Neuropsychiatric symptoms include apathy, agitation, aggression, anxiety,
depression, delusions, hallucinations, eating disorders and sleep impairment
(Lyketsos et al. 2002). The most common and widely used tool to evaluate
NPSs is the Neuropsychiatric Inventory (NPI) (Cummings 1997). Its
properties are discussed in more detail in section 4.4.1. Other tools used to
evaluate NPSs include the Cohen-Mansfield Agitation Inventory (CMAI), the
Behavioral Pathology in Alzheimer’s Disease rating scale (BEHAVE-AD), the
Brief Psychiatric Rating Scale (BPRS), the Geriatric Depression Scale (GDS)
and the Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos et al.
1988).
NPSs form clusters, and four neuropsychiatric subsyndromes: hyperactivity,
psychosis, affective symptoms, and apathy, have been identified (Aalten et al.
2007) (Figure 1).
Figure 1. Neuropsychiatric subsyndromes in dementia (Aalten et al. 2007).
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In a report from the European Alzheimer Disease Consortium the most
common subsyndrome was apathy, followed by affective symptoms (Aalten et
al. 2008). In a review by Zhao et al., apathy (49%) and depression (42%) were
also the most common NPSs, followed by aggression (40%), anxiety (39%) and
sleep impairment (39%). The less prevalent NPSs were disinhibition (17%),
hallucinations (16%) and euphoria (7%) (Zhao et al. 2016). People with
dementia are vulnerable to delirium, in which NPSs such as hallucinations and
delusions may be prominent (Inouye et al. 2014). In differential diagnostics,
possible underlying delirium should be considered, as symptoms of delirium
and multiple NPSs have been shown to be highly overlapping (Hölttä et al.
2011).
Neuropsychiatric symptoms have been reported to be very common among
both community-dwelling people with dementia as well as among long-term-
care residents. According to the Cardiovascular Health Study, 75% of dementia
participants exhibited NPSs (Lyketsos et al. 2002). According to the results of
various studies, the prevalence is 82–92% in long-term care settings (Pitkälä
et al. 2004, Selbæk et al. 2013, Björk et al. 2016). Several longitudinal studies
have revealed NPSs to be persistent, even though individual symptoms can
vary over time (Wetzels et al. 2010, Selbæk et al. 2014, Connors et al. 2018,
and Helvik et al. 2018).
2.1.2 RISK FACTORS AND ASSOCIATIONS WITH NPSs
Many factors have been found to be associated with the development of NPSs.
According to a review published in 2017 each NPS can have its own set of
specific determinants, but a number of determinants are common across
several symptoms (Kolanowski et al. 2017). Common NPS risk factors are
often divided into environmental factors, caregiver factors and patient factors
(Kales et al. 2015) (Figure 2).
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Figure 2. Three domains affecting the risk factors of NPSs (Kales et al. 2015)
Environmental factors encompass overstimulation and under-stimulation,
lack of activity and structure, and lack of established routines. When
considering caregiver factors, it is important to take into account
communication issues, lack of knowledge and education about dementia and
NPSs, stress, burden and possible caregiver depression (Feast et al. 2016,
Gerlach et al. 2018). Environmental and caregiver factors may trigger NPSs
independently or in interaction with brain-circuit disruptions caused by
neurodegeneration (Kales et al. 2015).  Patient factors cover a variety of factors
such as unmet needs, pain, fear, frustration, insecurity, hunger, acute medical
problems and premorbid personality or psychiatric disorders (Cohen-
Mansfield et al. 2015, Kales et. al 2015). It has also been proposed that instead
of being single events, NPSs are sequential, random, patterned clusters of
behavior, which can recur repeatedly in the same person, thus bringing
problems to symptom measurement, and evaluation of interventions
(Connors et al. 2018, Woods et al. 2018).
It has been argued that the disruption in brain circuitry caused by underlying
dementia leads to vulnerability to stressors and consequently to NPSs (Gerlach
et al. 2018). In addition to large-scale networks, brain volume has also been
shown to predict NPSs in Alzheimer’s disease (AD), with frontal lobe volume
being the strongest predictor (Boublay et al. 2020). Various dementia
subtypes have been argued to have their own characteristic neuropsychiatric
profiles (Cummings 1997), but not all investigators have reached this
conclusion (Aalten et al. 2008). Compared with Parkinson’s dementia,
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according to Aarsland (2001), aberrant motor behavior, agitation, apathy,
disinhibition, euphoria and irritability can be more severe in AD, while
patients with Parkinson’s dementia seem to have more hallucinations
(Aarsland et al. 2001). Compared with AD, people with frontotemporal
dementia can exhibit significantly more apathy, disinhibition and euphoria
(Levy et al. 2007). Patients with vascular dementia may be more likely to have
depression, and patients with dementia with Lewy bodies (DLB) have been
found more often to exhibit delusions and hallucinations than patients with
AD (Cummings 1997, Levy et al. 2007). A recent study also concerned the
association between cerebrospinal fluid (CSF) biomarkers and NPSs in cases
of AD. Lower levels of CSF amyloid-beta peptide-42 (Aβ42), higher levels of
tau protein and p-tau (phosphorylated tau) were associated with presence of
anxiety. Lower levels of CSF Aβ42 and smaller hippocampal volumes were
associated with the presence of apathy. All associations were mediated by
cognitive functioning (Banning et al. 2020).
Neuropsychiatric symptoms have been associated with the severity of
cognitive impairment and declining functional abilities (Cummings 1997,
Kolanowski et al. 2017). Several studies have shown that having NPSs impairs
quality of life in both community-dwelling and institutionalized older adults
with dementia (Hurt et al. 2008, Wetzels et al. 2010, Karttunen et al. 2011,
Mjørud et al. 2014, Conde-Sala et al. 2016, Klapwijk et al. 2016, Hongisto et
al. 2018). However, most of these studies have been conducted among people
with mild or moderate dementia and the generalizability of the results among
older adults with severe dementia can be questioned.
2.1.3 NON-PHARMACOLOGICAL TREATMENT OF NPSs
Non-pharmacological strategies are recommended as first-line treatment of
NPSs (Kales et al. 2019). They have been studied extensively, as there have
been more than 150 trials exploring their efficacy (Abraha et al. 2017, Dyer et
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al. 2018, Hölttä et al. 2019) (Table 1. Evidence of the effects of non-
pharmacological interventions in the treatment of neuropsychiatric symptoms
of dementia). Unfortunately, there are several limitations when considering
the evidence of efficacy, and implementation of non-pharmacological
interventions. One example is the challenge of comparing different non-
pharmacological treatment strategies. The majority of the studies have shown
great variation in how the same type of intervention has been defined and
applied. In addition, the populations, measures, follow-up duration and types
of outcome have varied.
According to the best evidence available, behavioral management techniques,
caregiver-based interventions or staff training in communication skills,
person-centered care or dementia care mapping, and music-based therapies
have been found to be the most effective treatment options (Abraha et al. 2017,
Dyer et al. 2018, Hölttä et al. 2019). One of the most widely used approaches
is the DICE approach (Kales et al. 2014). DICE is short for Describe,
Investigate, Create and Evaluate. Another model is TIME (Targeted
Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric
Symptoms) (Lichtwarck et al.  2018). Both models use a structured
interdisciplinary biopsychosocial approach that consists of making a
comprehensive assessment of underlying causes of neuropsychiatric
symptoms and an individually tailored treatment plan.
There is no positive evidence concerning the use of cognitive training,
cognitive stimulation, massage therapy, light therapy, aromatherapy, sensory
garden or horticultural activities (Viggo Hansen et al. 2006, Chung et al. 2002,
Woods et al. 2012, Forbes et al. 2014, Forrester et al. 2014, Gonzalez et al.
2014, Bahar-Fuchs et al. 2019). Data on the effectiveness of validation,
reminiscence therapy, simulated presence and therapeutic design is
inconsistent (Abraha et al. 2017, Woods et al. 2018). There is some preliminary
evidence concerning the use of animal therapy and pet robot therapy, but the
quality of evidence is poor and it comes from small trials (Lai et al. 2019, Leng
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et al. 2019). An additional challenge in all non-pharmacological trials is in
achieving blinding of participants and personnel.
The effectiveness of exercise on NPSs has also been studied, but the results are
somewhat contradictory (Barreto et al. 2015, Forbes, et al. 2015, Öhman et. al
2017). This could be due to the fact that NPSs have mostly been studied in
trials in which NPSs have been a secondary endpoint; thus Neuropsychiatric
Inventory (NPI) points at baseline have been relatively low, creating a possible
floor effect.
The international Delphi consensus process agreed in 2019 on DICE and
music therapy as the most promising non-pharmacologic treatment
approaches for overall NPSs and agitation (Kales et al. 2019). A stepwise
approach to the management of NPSs was also suggested.
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2.1.4 PHARMACOLOGICAL TREATMENT OF NPSs
Non-pharmacological treatment options are always the primary treatment
options for NPSs, because of the small effect sizes and the possible harmful
effects of pharmacological treatment (Sink et al. 2005, Kales et al. 2019) (Table
2. Evidence of the effects of pharmacological treatment of neuropsychiatric
symptoms of dementia). Despite this, pharmacological treatment is still widely
used. Such treatments are based on the neurobiological theoretical framework
in which NPSs result from synaptic or circuit disconnections in various brain
networks (Kales et al. 2015).
Pharmacological treatment may be considered only after significant efforts
have been made using non-pharmacological treatment. Treatment should be
used specifically in three specific scenarios, which may be more prone to
efficacy of drug treatment: major depressive disorder with or without suicidal
ideation, psychosis causing harm or potential for harm, and aggression with
risk to self or others (Kales et al. 2014). Pharmacological treatment options
consist of use of cognitive enhancers or psychotropics, which include
antipsychotics, antidepressants, anxiolytics, hypnotics and sedatives. Other
CNS drugs such as anticonvulsants and opioids have also been studied.
Current Care Guidelines in Finland recommend cognitive enhancers as first-
line drug treatment for NPSs (Memory Disorders: Current Care Guidelines,
2017).
The drugs of choice should be targeted to specific symptoms (Figure 3). Close
attention should be paid to the evidence of medication efficacy in relation to
specific symptoms, and the overall risks associated with untreated symptoms
compared with those connected to the medication.
28
When medication is initiated for NPSs, the persistence of symptoms should be
assessed thoroughly to determine if patients benefit from continued
medication versus drug discontinuation, while taking into account the
possibility of symptomatic relapse and possible subsequent decline (Phan et
al. 2019). In the United States no drugs have been approved by the Food and
Drug Administration for the treatment of NPSs. In Finland, however,
risperidone is approved for symptomatic management of severe NPSs
(Memory Disorders: Current Care Guidelines, 2017).
Figure 3. Non-pharmacological and pharmacological treatments used for
different neuropsychiatric subsyndromes (modified from Kales et al. 2015,
Kales et al. 2019, Hölttä and Pitkälä 2019). SSRI = serotonin selective reuptake
inhibitor.
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2.1.4.1 Cognitive enhancers
Cognitive enhancers such as cholinesterase inhibitors (ChEIs) and memantine
are used in primary treatment of the cognitive symptoms of Alzheimer’s
disease, but the results of a systematic review and a meta-analysis have
suggested that such types of medication may also help to alleviate NPSs (Trinh
et al. 2003, Birks 2006). In Finland cognitive enhancers are seen as part of the
first-line pharmacological treatment of NPS (Memory Disorders: Current Care
Guidelines, 2017). Recent study findings on their effectiveness are somewhat
contradictory. In 2018 a Cochrane review showed no significant difference
between donepezil and placebo as regards behavioral symptoms measured by
the NPI (Birks et al. 2018), but the combination of donepezil and memantine
was found to significantly improve behavior versus placebo (Tricco el al.
2018). A recent Cochrane systematic review also revealed strong evidence that
memantine has a small beneficial effect on mood and behavior (McShane et
al.  2019). These results must be interpreted with caution, because they are
based on clinical trials of relatively short duration, and NPSs tend to fluctuate
with time.
2.1.4.2 Antipsychotic medication
One of the most commonly used classes of drugs for pharmacological
treatment of NPSs is the class of antipsychotics (Olsson et al. 2010, Janus et
al. 2016). They also have the strongest evidence base (Kales et al. 2015).
However, the treatment effects are small, effect sizes being 0.13–0.16, and are
mainly seen in reducing aggressive behavior and psychotic symptoms (Kales
et al. 2015).  According to a Cochrane review, risperidone and olanzapine are
useful in reducing aggression, and risperidone in alleviating psychosis, but
both are associated with serious risks of adverse effects, such as death,
cerebrovascular events and extrapyramidal symptoms (Schneider et al. 2005,
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Ballard et al. 2006). Other possible side effects include cognitive decline,
somnolence, orthostatic hypotension, abnormal gait, falls, QT prolongation
and metabolic effects such as weight gain, dyslipidemia and diabetes
(Schneider et al. 2006).
A Cochrane review published in 2018 suggests that antipsychotics may be
successfully discontinued in older people with dementia and NPSs who have
been taking antipsychotics for at least three months. The authors found that
discontinuation may have little or no important effect on behavioral and
psychological symptoms (Van Leeuwen et al. 2018). This is consistent with the
observation that most NPSs in dementia are intermittent and often do not
persist for longer than three months. Based on the trials in this review, there
is still uncertainty as to whether or not discontinuation of antipsychotics leads
to a decrease in excess mortality. The balance of possible harms and benefits
of antipsychotic drug use for the treatment of NPSs must be individually
assessed. People with psychosis, aggression or agitation who responded well
to long-term antipsychotic drug use, or those with more severe NPSs at
baseline, may benefit behaviorally from continuation of antipsychotics,
whereas discontinuation may reduce agitation among people with mild NPSs
at baseline (Van Leeuwen et al. 2018). However, these conclusions are based
on only a few studies and small subgroups. Further evidence of benefits and
harms associated with withdrawal of antipsychotic medication is required
(Van Leeuwen et al. 2018).
2.1.4.3 Antidepressant medication
Another commonly used class of drugs for the treatment of NPSs is the class
of antidepressant drugs. According to a Cochrane review published in 2018,
available evidence does not provide strong support for the efficacy of
antidepressants for treating depression in dementia, especially beyond 12
weeks (Dudas et al. 2018). The evidence on remission rates favored
antidepressants but it was of moderate quality. Antidepressant medication,
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especially selective serotonin reuptake inhibitors (SSRIs), may have efficacy
for treating agitation, but the possible cognitive and cardiac adverse effects
may limit its application (Seitz et al. 2011, Porsteinsson et al. 2014). There is
evidence that antidepressant treatment may cause adverse events such as falls,
sleep changes, nausea, vomiting, hyponatremia and QT prolongation
(Hartikainen et al. 2007, Porsteinsson et al. 2014, Dudas et al. 2018, Seppälä
et al. 2019). According to the latest Beers criteria, tricyclic antidepressants
(TCAs) and other drugs with significant anticholinergic effects, such as
paroxetine, should be particularly avoided (Fick et al. 2019). Low-dose
mirtazapine is often used off-label for sleep problems in dementia, but there
is no data supporting this action (McCleery et al. 2014).
2.1.4.4 Anxiolytics and hypnotics
While sleep disorders are a common complaint in patients with dementia,
with > 50% of patients affected at the more severe stages of the disease (Kazui
et al. 2016), there is a lack of evidence on the use of anxiolytics and hypnotics
in people with dementia. In particular, there are no RCTs of drugs that are
widely prescribed for sleep problems in dementia, including the
benzodiazepine and non-benzodiazepine hypnotics (McCleery et al. 2016).
There is considerable uncertainty about the balance of benefits and risks
associated with these common treatments. Benzodiazepines constitute one of
the main risk factors of falls and fractures in older people. They seem to be
associated with an increased risk of falls not only in long-term use but also
after a new prescription (Hartikainen et al. 2007). A Cohrane review published
in 2016 showed no evidence that melatonin (up to 10 mg) helped sleep
problems in patients with moderate to severe dementia due to AD (McCleery
et al. 2016). NICE guidelines for dementia do not recommend melatonin for
people with dementia (NICE, 2018).  There is some evidence to support the
use of a low dose (50 mg) of trazodone, but the evidence is weak, and trazodone
seems to be no safer than benzodiazepines as regards falls (Bronskill et al.
2018). There is no evidence of any effect of ramelteon on sleep in patients with
dementia (McCleery et al. 2016).
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2.1.4.5 Other drugs for NPSs
Available studies carried out to evaluate the use of anticonvulsants such as
valproic acid, carbamazepine, pregabalin and gabapentin have not shown clear
evidence of benefit and they are associated with increased risks of adverse
effects and mortality (Kim et al. 2008, Konovalov et al. 2008). A Cochrane
review published in 2018 supported earlier findings that valproate
preparations are probably ineffective in treating agitation in people with
dementia, and they are also associated with an elevated rate of adverse effects.
On the basis of current evidence, valproate therapy cannot be recommended
for management of agitation in dementia (Baillon et al. 2018).
Pain may be one cause of agitation in dementia. Many older people with
dementia also have chronic, painful conditions. Pain may be experienced
differently due to the dementia and may often go uncommunicated or
untreated. It can be hard to know whether agitation is due to pain. In a cluster
randomized trial in Norway a systematic approach to the management of pain
significantly reduced agitation among long-term-care residents (Husebø et al.
2011). It has been hypothesized that opioids may be useful in the treatment of
agitation, where pain is an underlying factor, but they may also be effective for
relieving distress in the absence of physical pain. In a Cochrane review (2015)
it was found that there is no high-quality evidence to determine whether
opioids are a safe or effective treatment for agitation in dementia (Brown et al.
2015). Compared with nonuse, long-term opioid therapy is associated with
increased risks of abuse, overdose, falls and fractures, with several studies
showing dose-dependent associations (Chou et al. 2015, Seppälä et al. 2018).
Opioid use has also been associated with cognitive decline (Wright et al.
2009).
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2.1.4.6 Temporal trends in the use of psychotropics
Based on the results of various studies reporting serious adverse effects of
psychotropic drug use for the treatment of NPSs, a reduction of inappropriate
use has been of interest as regards governmental policies. As early as in 1987,
OBRA (Omnibus Budget Reconciliation Act) in the United States
recommended reducing the use of psychotropic drugs. Antipsychotic drug use
in US nursing homes (NHs) declined after implementation of this regulation,
whereas the use of antidepressants increased between 1996 and 2006
(Garrard et al. 1995, Hanlon et al. 2010). The latest report (2020) shows an
increase in the use of psychotropics, as the percentages of NH residents in the
US receiving anxiolytics, antidepressants, and antipsychotics in 1995 were
15%, 20%, and 16%, respectively, and by 2015 these figures had increased to
23%, 49% and 20% (Fashaw et al. 2020).
In 2012, to address the high level of use of antipsychotics in older adults with
dementia in US nursing-home settings, the Centers for Medicare & Medicaid
Services (CMS) launched the National Partnership to Improve Dementia Care
in Nursing in order to improve the quality of care for nursing-home residents
with dementia, primarily by reducing antipsychotic use. The program led to a
significant reduction in antipsychotic use from 24% in 2011 to 14.3% in 2019
(CMS, 2020). Unfortunately, there are indications of compensatory increases
in the use of other sedating psychotropics, not measured by the CMS, as well
as mood stabilizers (Maust et al. 2018). Thus, measuring only the use of
antipsychotics may be an inadequate proxy for quality of care and may
contribute to a shift in prescribing alternative types of medication such as
opioids and antiepileptics, with an even poorer risk-benefit balance (Maust et
al. 2018, Kales et al 2019). This case serves as an important reminder to look
at the big picture and not just a single piece of the puzzle.
In Finland, the prevalence of psychotropic drug use has been reported to be
higher in community-dwelling people with AD compared with people without
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AD (Taipale et al. 2014). According to a 2018 study, the prevalence of
psychotropic medication five years after AD diagnosis was 49.9% in people
with AD compared with 25.9% in people without AD (Orsel et al. 2018.). A
recent Swedish study revealed that AD patients who used ChEIs had a lower
risk of antipsychotic and anxiolytic use initiation (Tan et al. 2020). The
prevalence of psychotropic drug use in Europe and Australia is more common
in long-term-care residents, varying between 52–80% in nursing homes and
53–68% in assisted-living facilities, according to the results of various studies
(Hosia-Randell et al. 2005, Selbæk et al. 2007, Stafford et al. 2011, Richter et
al. 2012, Rolland et al. 2012, Pitkälä et al. 2015, Helvik et al. 2017).
Given concerns about changing trends in CNS and psychotropic medication
use globally, and the many factors that influence their use, a current
assessment of psychotropic medication use in Finnish long-term care settings
is required.
2.2 DEMENTIA
To obtain a better understanding of NPSs in dementia, it is important to fully
understand underlying dementia. Dementia is defined as a syndrome in which
there is deterioration in cognitive function beyond what might be expected
from normal ageing (WHO, 2019). The core criteria also require that there is
a decline from a previous level of functioning and that symptoms significantly
interfere with the ability to function when carrying out usual activities
(McKhann et al. 2012).
According to the criteria of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) classification, neurocognitive disorders are divided into
major NCDs, minor NCDs and delirium (APA, 2013). Dementia is included
under major NCDs and is in turn divided into Alzheimer’s disease (AD),
vascular dementia (VAD), Dementia with Lewy bodies (DLB), Parkinson´s
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disease dementia (PDD), frontotemporal dementia (FTD) and alcohol-related
dementia.
Other widely used criteria include those of ICD-10 (WHO 1993) and the
National Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ARDRA) criteria for AD (McKhann et al. 2011). The core features of dementia
in all criteria include significant cognitive decline from a previous level and its
interference with daily functioning. In addition, all criteria include NPSs as an
additional qualifying feature. NINCDS-ARDRA criteria to diagnose AD are
used in both clinical practice and research. These criteria were last revised in
2011 (McKhann et al. 2011). In clinical work the most often used diagnostic
criteria for AD at present are those of the International Classification of
Diseases, 10th edition (ICD-10) (WHO, 1993). Its latest edition (ICD-11) was
released in May 2019, but it is not yet in clinical use. The manual DSM-5 is
commonly employed in mental-health research (APA 2013).
The term ‘dementia’ originates from the Latin word ‘demens’, originally
meaning ‘madness’ or being out of one's mind. The use of the word dementia
has been questioned, as the term can be seen as pejorative and stigmatizing
(Trachtenberg et al. 2008). It has been suggested that it would be better to
simply refer to each neurocognitive disorder as a specific disease (e.g. AD, VCI
or FTLD etc.), which could be seen as a logical resolution to the terminology
problem (Jellinger et al. 2010). When a general term is needed, then
neurocognitive disorder could be a clear, truthful, and nonpejorative option.
In DSM-5 the term dementia has been replaced with “major and mild NCD” in
an effort to reduce the stigma attached to the term dementia (APA, 2013). In
Finland, in the Current Care Guidelines, the term “memory disorder” is used
instead of dementia (Memory Disorders: Current Care Guidelines, 2017). In
addition, the phrase “dementia-friendly” was replaced by “memory-friendly”
when in the National Memory Programme 2012–2020 “Creating a memory-
friendly Finland” was established (Finnish Ministry of Social Affairs and
Health, 2013). Globally, however, the word “dementia” is still very much used
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in clinical practice and in a research context. For this reason, as a general term
the word “dementia” will be used in this thesis.
2.2.1 EPIDEMIOLOGY OF DEMENTIA
According to the World Health Organization (WHO) around 50 million people
worldwide have dementia. Every year, there are almost 10 million new cases,
one every three seconds. The total number of people with dementia is
predicted to reach 82 million in 2030 and 152 million in 2050 (WHO, 2019).
In Finland, approximately 190,000 people have a memory disease and there
are approximately 14,500 new cases of dementia each year (Memory
Disorders: Current Care Guidelines 2017). Thus, dementia constitutes an
increasing challenge to healthcare systems worldwide (Nichols et al. 2016).
The worldwide age-standardized prevalence of dementia in the general
population aged 60 and over at a given time is between 5–8% and it varies
little between world regions (Prince et al. 2013). Alzheimer Europe compared
the prevalence of dementia between the different European countries in 2013.
The average prevalence rate for dementia in Europe was 1.55%. In Finland it
was slightly higher, being 1.71%. The highest prevalence was in Italy, 2.09%.
Slovakia, Ireland and Cyprus had the lowest rates of prevalence, 1.07–1.08%
(Alzheimer Europe, 2013). These results should be interpreted with caution,
as changes in the prevalence of dementia can be modulated by a complex
combination of societal determinants affecting diagnostic processes, survival
and lifestyle factors. Another factor to consider is that the prevalence rates are
likely to be affected by increased attention to dementia and awareness of it,
shifting diagnostic boundaries and the age structure of each population (Wu
et al. 2016).
A growing number of studies have revealed a decline in the prevalence or
incidence of dementia in Western countries (Matthews et al. 2013, Wu et al.
2017, Harrison et al. 2020). Even so, as the population is aging, the absolute
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number of dementia cases will continue to grow despite the decreasing
prevalence. The good news is that dementia morbidity seems to be on a down-
turn, at least in high-income countries. In the Framingham Heart Study it was
found that the age at dementia onset has increased on average by around 1.5
years, whereas years alive with dementia have decreased on average by one
year over time (Dufouil et al. 2018). There are no data yet from low-income
countries, where populations are aging most rapidly. As prevalence is a
function of incidence and duration of survival with the disease, careful
investigation into the trajectories of dementia are needed to ascertain service
needs in the future (Ganguli et al. 2017).
2.2.2 RISK FACTORS OF DEMENTIA
Age is the strongest risk factor of cognitive decline, as both the incidence and
the prevalence of dementia increase exponentially with increasing age
(Corrada et al. 2010, Lucca et al. 2015). However, aging without dementia is
possible (Qiu et al. 2018). The results of several recent studies have shown that
lifestyle-related risk factors have a relationship with the development of
dementia (Kivipelto et al. 2018, Ngandu et al. 2015, Lourida et al. 2019).  These
risk factors include physical inactivity, an unhealthy diet (such as low intake
of fruits, vegetables and whole grains and high intake of saturated fats, sugar
and salt), harmful use of alcohol or tobacco and a low level of education. In a
recent study it was also suggested that more frequent social contact in middle-
age years is associated with a lower dementia risk in older age (Sommerlad et
al. 2019). The link from frequent social contact to a lower dementia risk could
be a development of a higher cognitive reserve, although it is possible that the
ability to maintain more social contact may be a marker of cognitive reserve
itself.
Some chronic medical conditions are also associated with an increased risk of
dementia, including hypertension, diabetes, hypercholesterolemia, obesity
and depression (Livingston et al. 2017, Strandberg et al. 2019). With respect
to genetic factors, APOE e4 is the strongest predictor of Alzheimer’s disease
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(Hersi et al. 2018). Also, groups of people on specific forms of medication, such
as those on anticholinergic medication have been suggested to be at an
increased risk of dementia (Coupland et al. 2019).
The existence of these potentially modifiable risk factors makes dementia
prevention possible through a public-health approach, as the proactive
management of modifiable risk factors has been shown to delay or slow down
the onset or progression of the disease (Kivipelto et al. 2018). In the Finnish
Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
(FINGER), the largest completed trial so far, 1260 individuals aged 60–77
years with an increased dementia risk score were randomly assigned to receive
multidomain lifestyle counselling including nutritional guidance, group and
individual physical activity, cognitive training, and intensive monitoring of
vascular and metabolic risk factors (n=631), or regular health advice (n=629)
(Ngandu et al. 2015). At baseline, all participants were given oral and written
information and advice on a healthy diet and physical, cognitive, and social
activities beneficial for management of vascular risk factors and disability
prevention. The intervention group additionally received four intervention
components. Cognitive function improved significantly during the two years
of intervention in both groups, but the intervention group improved
significantly more than the control group. The challenge with the intervention
is that it was long and very intensive, which makes it hard to replicate in the
real world. Follow-up of the FINGER study is still ongoing. In time it will also
show the effect of the intervention on the incidence of dementia. A CAIDE
Dementia Risk Score App has been developed as an evidence-based mobile
application to predict the risk of dementia (Kivipelto et al. 2006, Sindi et al.
2015). The App is meant to encourage users to actively decrease their
modifiable risk factors and hence postpone cognitive impairment and
dementia. A CAIDE score was used as an inclusion criterion in the FINGER
study.
Other multidomain lifestyle interventions carried out in recent years include
the French Multidomain Alzheimer Preventive Trial (MAPT) and the Dutch
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Prevention of Dementia by Intensive Vascular Care (PreDIVA) trial (Kivipelto
et al. 2018). The primary outcomes were cognition measured by a composite
score (MAPT), and dementia incidence (PreDIVA). Neither the MAPT nor the
PreDIVA RCTs accomplished their primary endpoints, but they showed
beneficial effects of intervention in specific subgroups of participants. The
PreDIVA trial revealed a reduced risk of non-AD dementia in the intervention
group. The MAPT trialists reported less decline in the intervention group in
ten MMSE orientation items compared with the control group, but no
difference in other cognitive outcomes was found. One explanation for these
less than encouraging results could be the lower intensity of the intervention
measures compared with those in the FINGER trial.
WHO Guidelines on reduction of risk of cognitive decline and dementia were
published in May 2019 (WHO, 2019). These guidelines give recommendations
concerning twelve different risk factors: low levels of physical activity,
smoking, poor diet, alcohol misuse, insufficient or impaired cognitive reserve,
lack of social activity, unhealthy weight gain, hypertension, diabetes,
dyslipidemia, depression, and hearing loss.
2.2.3 DIAGNOSIS OF DEMENTIA
Timely and accurate diagnosis of any neurocognitive disorder is crucial as this
enables correct treatment and a rehabilitation plan and will help families plan
ahead (Dassel et al. 2019). A timely diagnosis can also reduce unnecessary
suffering and increase family members’ understanding of dementia and NPSs
even though no disease-modifying treatment is yet available. On the other
hand, overdiagnosis of dementia, such as identification of characteristic AD
pathology, e.g. amyloid plaques in the brain (although these may never lead to
dementia) can expose individuals to adverse effects and complications. This
will also increase costs of diagnosis and treatment without the benefit of
preventing a clinically significant disease (Langa et al. 2019). It is known from
various studies that more than half of the individuals with MCI will not
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progress to dementia (Canevelli et al. 2016, Ganguli et al. 2019, Shimada et al.
2019). Some will remain stable and some might even revert to normal
cognition; thus they should not all be subjected to the same therapeutic
strategies.
Especially in older populations, the diagnostic process can be complicated, as
there are various other factors affecting cognition, such as poor vision, hearing
and multimorbidity. These should always be taken into account when
interpreting the diagnostic work-up. Differential diagnostics can also pose a
challenge, especially when differentiating dementia with NPSs from delirium
(Hölttä et al. 2011). Delirium reflects a rapid change in brain function with
disturbances in arousal and attention, whereas dementia develops over time,
with slow progression (Inouye et al.2014).
The most common progressive neurocognitive disorder leading to dementia is
Alzheimer's disease (AD) (WHO, 2019). This is a neurodegenerative disorder
currently assumed to be caused by amyloid plaques and neurofibrillary tangles
accumulating in the brain (Perl, 2010). Studies published in the recent years
have shown that AD seems to be an umbrella term including different types of
disorder (Murray et al. 2011).  The second most prevalent cause of dementia is
vascular dementia (VAD), which can be caused by various types of vascular
pathologies in the brain, such as “large vessel” (strategic infarctions or multi-
infarct dementia) or “small vessel” (subcortical lacunar infarcts and white
matter hyperintensities) disease (O’Brien et al. 2015). Especially in older age,
symptoms and brain changes of different dementias often overlap. Mixed
dementia caused by vascular cognitive impairment (VCI) and AD has emerged
as the leading cause of age-related cognitive impairment (Iadecola 2013).
Other less frequent causes of dementia include frontotemporal lobar
degeneration (FTLD), including the behavior variant frontotemporal
dementia, and primary progressive aphasias, dementia with Lewy bodies
(DLB) and Parkinson’s disease dementia (PDD). There are also several other
diseases that can lead to dementia, such as normal pressure hydrocephalus
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and Parkinson-plus syndromes such as multiple-system atrophy (MSA),
progressive supranuclear palsy (PSP) and cortical-basal ganglionic
degeneration (CBGD) (Memory Disorders: Current Care Guidelines, 2017). In
the last five years two new disease entities have been recognized: a “limbic-
predominant age-related TDP-43 encephalopathy” (LATE) and a “primary
age-related tauopathy” (PART) (Crary et al. 2014, Nelson et al. 2019). Their
clinical significance and relationship to AD is still under ongoing research.
2.2.4 MANAGEMENT OF DEMENTIA
Treatment of dementia depends on its cause. No disease-modifying treatment
is available to date, but there are four drug treatments for AD that may
temporarily improve the different symptoms caused by the disease
(Galimberti et al. 2011). They are also widely used for controlling the NPSs of
dementia.
Donepezil, rivastigmine, and galantamine are all cholinesterase inhibitors
(ChEIs). They have been on the market for approximately 20 years, as
donepezil was approved in 1997. They are considered to represent first-line
pharmacotherapy for mild to moderate Alzheimer’s disease and for the
treatment of NPSs (Memory Disorders: Current Care Guidelines 2017, NICE
2018, Joe et al. 2019). They act by increasing the availability of acetylcholine
in the extracellular space, which in turn promotes neuronal activity and
cholinergic signaling in the brain (Francis et al. 1999). Cholinesterase
inhibitors have been found to be effective in improving cognitive functioning
in patients with mild to severe AD (Joe et al. 2019). However, the effect sizes
found in clinical trials have been small to moderate (0.15–0.28, depending on
the dose) (Rockwood 2004, Kaduszkiewicz et al. 2005, Birks 2006). Another
limitation may be the generalizability of the data: many older people with
dementia also have other comorbidities, excluding them from clinical trials.
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Despite the small variations in the mode of action of the three ChEIs there is
no evidence of any differences between them with respect to efficacy (Birks
2006).  There seem to be some differences in adverse effects, with fewer
adverse effects associated with donepezil compared with oral rivastigmine
(Birks 2006, Birks et al. 2018). Donepezil is the most widely used ChEI in
Finland, probably because of its relatively good tolerability and easier titration
routine (Linna et al. 2019). Cholinesterase inhibitors are associated with
possible gastrointestinal and cardiopulmonary side effects as well as dizziness,
headache, insomnia, incontinence, and muscle cramps (Birks 2006, Tricco el
al. 2018). Donepezil has been proved to be cost-effective (Birks et al. 2018).
The fourth drug approved for the treatment of AD is memantine, which is an
NMDA (N-methyl-d-aspartate) receptor antagonist affecting glutamate
metabolism and blocking the toxic effects of overactive glutamatergic activity
(Johnson et al. 2006). The efficacy of memantine has been proved in cases of
moderate-to-severe AD in monotherapy or in combination with a ChEI
(Matsunaga et al. 2015, McShane et al. 2019). Possible side effects of
memantine include headache and dizziness, but overall, memantine is better
tolerated than the ChEIs (McShane et al. 2019).
The same medications that are used to treat AD are among the drugs
prescribed to control symptoms of other types of dementia, such as LBD and
PDD (Rolinski et al. 2012, Walker et al. 2015). The questionable efficacy of AD
medication in cases of VAD, combined with concerns over possible adverse
effects, has led to guidelines concluding that cholinesterase inhibitors and
memantine should not be used in patients with pure VAD, but may be used in
those with a combination of VAD and AD (Erkinjuntti et al. 2002, O’Brien et
al. 2015, Birks et al. 2006, Birks et al. 2013).
As there have been no significant advances in the pharmacological treatment
of dementia in recent years, the focus has moved more to non-pharmacological
therapies. There is promising evidence that improvements brought about by
way of non-pharmacological interventions are of similar effect size as with
45
pharmacological treatments but with fewer side effects. The most promising
non-pharmacological treatments are multicomponent interventions including
individual assessment, exercise, nutrition, case management and cognitive
stimulation (Olazarán et al. 2010).
Available evidence suggests that exercise programs may maintain physical
functioning and prevent falls in people with dementia (Pitkälä et al. 2013,
Burton el al. 2015, Forbes et al. 2014). Tailored nutritional guidance has also
been found to enhance nutrition and quality of life and to prevent falls among
community-dwelling individuals with Alzheimer’s disease (Suominen et al.
2015). Case management of elderly couples with dementia has been shown to
lead to reduction in use and expenditure of municipal services (Eloniemi-
Sulkava et al. 2009). Self-management group rehabilitation for persons with
early dementia and their spouses has been shown to have beneficial effects on
the health-related quality of life (HRQoL) of spouses and cognitive function
among people with dementia, without increasing total costs (Laakkonen et al.
2016). There is also consistent evidence from various trials concerning the
benefits of cognitive stimulation programs on cognition in people with mild to
moderate dementia, although the quality of the evidence has been questioned,
as the studies have had limited sample sizes and limited information on
randomization (Woods et al. 2012).
Supporting evidence for the use of occupational therapy, complementary and
alternative medicine, and new technologies, including information and
communication technologies, assistive technology and domotics, virtual
reality, gaming and telemedicine is still preliminary (Zucchella et al. 2018).
According to the results of a 12-week RCT in Finland, systematic cognitive
training did not have an effect on global cognition or HRQoL in community-
living people with mild to moderate dementia (Kallio et al. 2018).
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2.2.5 DEMENTIA IN LONG-TERM CARE
As dementia progresses it often leads to institutional care. In Finland, as in
other Western countries, a large proportion of residents in institutional care
have dementia. There were 54 411 older people in permanent institutional care
(including nursing homes and assisted-living facilities) in Finland in 2018
(Finnish Institute for Health and Welfare, 2019). It has been estimated that
more than 70% of long-term-care residents in Finland have severe or very
severe cognitive decline (Finne-Soveri et al. 2015). Similarly, in the UK, up to
73% of NH residents have dementia (Alzheimer’s Society, 2014).
In a Finnish register-based study, people with dementia used long-term care
nine times more often (OR 9.30) than people without dementia (Forma et al.
2011).
2.2.6 PROGNOSIS OF DEMENTIA
Cognitive decline, disability and NPSs in dementia increase over time,
although the rate at which the disease progresses varies (Strand et al. 2018).
As the clinical course of dementia is gradual, it is useful to distinguish between
various levels of severity. Dementia is most commonly divided into four stages:
very mild, mild, moderate and severe dementia, in, for example, the clinical
dementia rating (CDR) scale (Hughes et al. 1982). The CDR scale has been
shown to correlate well with ADL and IADL scales, and moderately well with
DSM-III-R criteria (Juva et al. 1994).
Survival after dementia diagnosis varies considerably and depends on various
factors and their complex interaction (Brodaty et al. 2012). Worse cognition,
male gender, higher number of types of medication, institutionalization, and
age have been associated with increased death risk after dementia diagnosis
(Garcia-Ptacek et al. 2014). Rates of survival and years of life lost vary between
the different etiologies. People with VAD, DLB or PDD have the shortest
survival times, followed by mixed dementia, and AD (Strand et al. 2018). A UK
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population study revealed a median survival time from diagnosis of dementia
to death of 4·1 years (Xie et al. 2008). In this study 72% of the participants had
an MMSE score of less than 21/30 at the time of diagnosis.  A more recent
study carried out in Spain showed the median survival time from diagnosis of
dementia to death to be 5·2 years (Garre-Olmo et al. 2019). These results are
in line with those of a systematic review published in 2013, which reported
median survival times from diagnosis to death ranging from 3.2–6.6 years
(Todd et al. 2013). In a study carried out in Norway, VAD/DLB/PDD were
associated with a life expectancy of 4.6 years in women and 4.7 years in men,
whereas in cases of AD life expectancy was 7.5 years in women and 5.8 years
in men (Strand et al. 2018).
2.3 FALLS
A fall is defined as an unexpected event whereby a person involuntarily comes
to lie on the ground or another lower level with or without loss of
consciousness (Lamb et al. 2005). The relationship between falls and
dementia is complex. Both falls and cognitive impairment are prevalent
among older adults, and the incidence of both increases with age (Bridenbaugh
et al. 2015). Mobility problems and cognitive impairment often exist side by
side and their temporal relationship appears to be bi-directional (Davis et al.
2015.)
Gait in older adults is a motor-cognitive task, where attention, executive
functioning and memory are needed (Pichierri et al. 2011, Fernando et al.
2017). It has been argued that understanding the relationship between
cognitive changes and gait disturbances could help to identify older adults at
higher risk of progression to dementia, mobility decline or falls (Montero-
Odasso et al. 2012, Modarresi et al. 2018).
48
2.3.1 EPIDEMIOLOGY OF FALLS
At least one-third of community-dwelling people over 65 years of age fall each
year (Tinetti et al. 1988). People with dementia have a significantly higher risk
of falling than those without dementia. The risk is twice as high in community-
dwelling people with dementia as in those without dementia (Welmerink et al.
2010). The fall risk is even higher in nursing-home residents with dementia.
Approximately half of nursing-home residents fall annually, a proportion that
is two to three times that of community-dwelling residents (van Doorn et al.
2003).
The matter is of great importance, as the number of people with dementia is
growing. Falls are major contributors to premature nursing-home placement
(Tinetti et al. 1997). Higher dementia prevalence can lead to a higher
prevalence of falls, which intrinsically leads to a higher number of fractures
and head injuries, increasing healthcare and economic burdens, as well as
individual suffering (Davis et al. 2015).
2.3.2 RISK FACTORS OF FALLS
Most falls are not the result of a single cause, but occur because of interaction
of several risk factors (Berry et al. 2008). Risk factors of falls can be divided
into intrinsic and extrinsic risk factors. Major identified intrinsic causes of a
higher fall risk include previous falls, age, impaired cognition, impaired vision,
and hearing and executive function deficits (AGS 2001). Musculoskeletal
deficits and postural instability lead to impairments of gait and balance. In
addition, psychotropic drug use as well as polypharmacy, alcohol use,
malnutrition, neurocardiovascular diseases such as orthostatic hypotension,
plus incontinence and arthrosis have been associated with falls (Hartikainen
et al. 2007, Shaw et al. 2007, Herman et al. 2010, Deandrea et al. 2010, Tinetti
et al. 2010, Ambrose et al. 2013). Extrinsic risk factors include, for example,
lighting, furniture arrangements, clothing and footwear (AGS 2001).
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Several drug classes have been shown to expose older people to the risk of falls,
but the use of psychotropic medication is especially associated with falls
among older people (Hartikainen et al. 2007, Woolcott et al. 2009, Olazarán
et al. 2013, Seppälä et al. 2018, Yoshikawa et al. 2020) (Table 3. Studies on
CNS medication and fall risk). The results of very large and intermediate-
quality prospective cohort studies and case-control studies (n=8127–321 995)
suggest a significantly increased risk of falls among the elderly (Seppälä et al.
2018). In a recent review the OR for falls in connection with various
psychotropics were: 1.54 (95% CI 1.28–1.85) for all antipsychotics, 1.57 (95%
CI 1.43–1.74) for all anti-depressants, 1.41 (95% CI 1.07–1.86) for TCAs, 2.02
(95% CI 1.85–2.20) for SSRIs, 1.42 (95% CI 1.22–1.65) for all benzodiazepines,
1.81 (95% CI 1.05–3.16) for long-acting benzodiazepines and 1.27 (95% CI
1.04–1.56) for short-acting benzodiazepines (Seppälä et al. 2018).
Benzodiazepines have been considered to represent one of the main risk
factors of falls and fractures in older people, but it seems that antidepressants
and antipsychotics are no safer. These findings can partially be affected by
preferential prescribing, such as prescribing SSRIs to frail older adults with a
higher fall risk. There are very few data on other antidepressants. Low-dose
trazodone seems to be no safer than benzodiazepines (Bronskill et al. 2018).
Antipsychotic drugs as a group are also associated with an increased risk of
falling. It has been reported that the relative risk of falls ranges between 1.21
and 11.4 (Hartikainen et al. 2007). Opioids seem to have major effect sizes as
regards the risk of falls, fall-related injuries and fractures (Yoshikawa et al.
2020). According to the results of a recent trial among AD patients, the risk of
falls among those on psychotropics may be reduced by long-term exercise
(Perttilä et al. 2018).
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Polypharmacy, the use of five or more drugs, multiplies the risk of falling
(Seppälä et al. 2018). In particular, concomitant use of several CNS-affecting
drugs should be avoided. To my knowledge, there is only one study on
gabapentinoids. Mukai et al. (2019) retrieved data from spontaneous
reporting systems for adverse drug events in the US and Japan, and suggested
that pregabalin significantly increases the risk of falls. There are controversial
findings concerning the risk of falls in connection with antidementia drugs. In
RCTs,  no significant differences have been found between users and nonusers
of ChEIs and memantine (Seppälä et al. 2018).
The use of psychotropic drugs, behavioral symptoms, impaired mobility and
orthostatic hypotension have been shown to increase fall risk in nursing-home
residents (van Doorn et al. 2003, Allan et al. 2009, Whitney et al. 2012, Kosse
et al. 2015, Morley 2016, Cameron et al. 2018). Despite the high prevalence of
both falls and NPSs among older adults with dementia there are relatively few
studies exploring the association between NPSs and falls. The results of some
studies have suggested that NPSs predict falls (Hasegawa et al. 2010, Suzuki
et al. 2012, Sylliaas et al. 2012, Galik et al. 2018, Sato et al. 2018), but the
evidence is scarce. Additionally, what is not yet clear is the impact of NPS
severity on fall rate.
2.3.3 OUTCOMES OF FALLS
Most falls do not result in serious injury (van Doorn et al. 2003 Kosse et al.
2015, Galik et al. 2018). Only approximately 10% of those who fall suffer
serious injuries such as fractures or head trauma (Galik et al. 2018). Minor
injuries are more common and maybe present in 22–60% of fallers (Milat et
al. 2011). Fall-related negative consequences are more likely among those with
cognitive impairment (Thapa et al. 1996, Weller et al. 2004). Falls lead to
higher rates of morbidity and mortality and are major contributors to
immobility and premature nursing-home placement (Rubenstein 2006).
Long-term-care residents have been reported to have the highest incidence
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rates of hip fracture (Sugarman et al. 2002).  The mean incidence rate of hip
fractures across US long-term-care facilities in 2018 was 3.13 per 100 person-
years (Zullo et al. 2018).
Interestingly, ChEI use has recently been associated with reduced fracture risk
(Ogunwale et al. 2019, Tamimi et al. 2018). The suggested mechanism is that
ChEIs may confer protection against fractures by accelerating bone healing
and reducing both fracture complications and all-cause mortality post-hip
fracture. These results are preliminary and all possible confounders were not
adjusted for (e.g.  dementia type, severity and frailty).
Even though not all falls lead to injury, every fall is significant, as a previous
fall is an important risk factor of another fall (Rubenstein et al. 2006, Tinetti
et al. 2010).
2.3.4 EXERCISE INTERVENTIONS TO PREVENT FALLS IN DEMENTIA
PATIENTS
According to a recent Cochrane review there is high-certainty evidence that
exercise programs reduce the rate of falls and the number of people
experiencing falls when considering older people living in the community
(Sherrington et al. 2019). The evidence for fall reduction in older people with
dementia is not as consistent.
FINALEX, a Finnish Alzheimer disease exercise trial, an RCT carried out in
Finland, showed that an intensive and long-term exercise program has
beneficial effects on the physical functioning of patients with AD without
increasing the total costs of health and social services or causing any
significant adverse effects (Pitkälä et al. 2013). The participants were 210
home-dwelling patients with AD living with their spousal caregivers. In the
trial more falls occurred among control participants, although no differences
were recorded in the numbers of fractures or hospitalizations. This was one of
the first studies that showed that exercise may reduce the incidence of falls in
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patients with AD. A secondary analysis of FINALEX data revealed that exercise
intervention had a significant effect on the risk of falling among participants
with moderate or severe AD (CDR 2–3). Among participants in the
intervention group, the rate of falls was 1.78 falls/person per year, while
among those in the control group it was 3.76 falls/person per year (Öhman et
al. 2016).
The effect of exercise interventions for preventing falls in older people in care
facilities and hospitals is still uncertain. A recent study carried out in Sweden
showed that a high-intensity functional exercise program, as a single
intervention, did not prevent falls in people with dementia living in nursing
homes (Toots et al. 2019). The authors proposed that in high-risk populations
where multimorbidity and polypharmacy are common, a multifactorial fall-
prevention approach may be required (Toots et al. 2019). Another reason for
the contradictory results from this study could be the short duration of the
intervention, just four months, compared with 12 months in the FINALEX
intervention. A Cochrane review published in 2018 showed that exercise had
little or no effect on the risk of falling in care facilities (Cameron et al. 2018).
One problem with the review is that the quality of evidence in connection with
individual interventions was generally rated as low or very low.
The results of a systematic review and meta-analysis concerning the
effectiveness of exercise interventions in reducing falls in people with
dementia suggested that physical exercise has a positive effect on preventing
falls in older adults with cognitive impairment (Chan et al. 2015). Four of the
seven studies involved showed a significant effect in reducing the fall rate.
According to the authors, the core elements of successful intervention were
multicomponent exercise (a combination of strength, endurance, and balance
training), supervision of the training by a professional trainer, and an
individually tailored exercise program adapted to the cognitive level of the
participant (Chan et al. 2015). Probably because of attainment of sufficient
muscle strength, progressive resistance training seemed to be the most
effective exercise modality for improving gait speed (Van Abbema et al. 2015).
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Tai Chi practice may also be effective for preventing falls in older adults
(Huang et al. 2017). It may reduce the rate of falls by 43% and that of injury-
related falls by 50% over 12 months (Lomas-Vega et al. 2017).
Current research evidence therefore suggests that increased physical exercise
may not only decrease the number of falls but also slow the progression of
cognitive decline and physical function (Teri et al. 2008, Pitkälä et al. 2013,
Chan et al. 2015). Less is known about the effects of exercise on NPSs and if
exercise can modify the risk of falls among people with dementia and NPSs.
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2.4 HEALTH-RELATED QUALITY OF LIFE (HRQoL)
2.4.1 DEFINITION OF HRQoL
Understanding about quality of life (QoL) and HRQoL has advanced
significantly over the past 25 years. Formerly, QoL in medicine typically
concerned only objective measures, but in the early 1990s, a new
understanding also included subjective well-being (Cummins et al. 2015).
Nowadays WHO defines quality of life as an individual's perception of their
position in life in the context of the culture and value systems in which they
live and in relation to their goals, expectations, standards and concerns. It is a
broad concept affected in a complex way by the person's physical health,
psychological state, personal beliefs, social relationships and their relationship
to salient features of their environment (WHOQOL Group, 1994).
Health-related quality of life is also a multi-dimensional concept. It is
considered a part of general QoL. There are four fundamental dimensions that
are essential to any HRQoL measure. These include physical,
mental/psychological, and social health, as well as global perceptions of
function and well-being. Additional HRQoL domains considered important
but not always necessary include pain, energy/vitality, sleep, appetite, and
symptoms relevant to an intervention and the natural history of a disease or
condition (Berzon et al. 1993). Two basic approaches to quality-of-life
measurement are available: generic instruments that provide a summary of
HRQoL; and specific instruments that focus on problems associated with
single disease states, patient groups, or areas of function. Each approach has
its strengths and weaknesses and may be suitable for different circumstances
(Guyatt et al. 1993).
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2.4.2 MEASURES OF HRQoL
Several measures for assessing HRQoL have been developed that reflect
different conceptualizations of QoL (Ettema et al. 2005, Bowling et al. 2015).
The use of different measures makes it difficult to compare study results (Table
4. Comparison of different measures of HRQoL). Another question concerns
the use of self-reports or proxy measurements. It is known from previous
research that there are differences between caregiver assessed and self-rated
quality of life (Hoe et al. 2007, Hurt el at. 2008, Beerens et al. 2013, Hongisto
et al. 2018). Patients tend to consider their quality of life to be higher than do
caregivers. Both measures can be useful, as both can provide psychometrically
sound data, but when patients who have difficulty in understanding the
questions, for example as a result of severe dementia, are included, the
application of proxy measures should be preferred. Examples of different
measures of HRQoL in dementia, which can also be proxy-rated, include 15D
(15-dimensional instrument for measuring HRQoL), SF-36 (short-form health
survey with 36 questions), WHOQOL-Bref (World Health Organization
Quality of Life instrument with 26 items) and QUALID (Quality of Life in Late-
Stage Dementia Scale) measures (Sintonen 2001, Ware et al. 1992, WHOQOL
Group 1998, Weiner et al. 2000).
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Table 4. Comparison of selected measures of HRQoL
Dimension 15D SF-36 WHOQOL-Bref QUALID
Health and
physical well-
being
Mobility
Vision
Hearing, Breathing
Sleeping
Eating
Excretion
Discomfort and
symptoms
Vitality
Bodily pain
General health
Vitality
General health
Pain and discomfort
Dependency on medical
substances and medical aids
Mobility
Sleep and rest
Energy and fatigue
Has a facial expression
of discomfort
Appears physically
uncomfortable
Enjoys eating
Psychological
well-being
Depression, Distress
Mental function
Mental health
perceptions
Positive feelings
Negative feelings
Self-esteem
Bodily image and
appearance
Spirituality, religion and
personal belief
Thinking, learning,
memory and concentration
Smiles
Appears sad
Cries
Appears emotionally
calm and comfortable
Is irritable or aggressive
Makes statements or
sounds that suggest
discontent, unhappiness
or discomfort
Social
relationships
Speech (communication)
Sexual activity
Social functioning Personal relationships
Sexual activity
Social support
Enjoys touching/being
touched
Enjoys interacting or
being with others
Productivity
and
functioning
Usual activities Physical
functioning
Role limitations
because of health
problems
Activities of daily living
Work capacity
Participation in and
opportunities for recreation
and leisure activities
Environment
and material
well-being
Freedom, physical safety
and security
Physical environment
Financial resources
Home environment
Opportunities for acquiring
new skills and information
Transport
Health and social care:
accessibility and quality
15D (Sintonen 2001), SF-36 (Ware and Sherbourne 1992), WHOQOL-Bref (WHOQOL Group
1998), QUALID (Weiner et al. 2000) used for persons with dementia.
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2.4.3 HRQoL IN DEMENTIA
Without a cure, the main question in dementia care is how to promote well-
being and maintain an optimal QoL (Whitehouse et al. 2003). Unmet needs of
people with dementia living in nursing homes have been linked to worsening
NPSs and reduced QoL (Cohen-Mansfield et al. 2015). In a literature review,
self-reported needs and experiences of people with dementia in nursing homes
were explored, revealing eight specific themes to be linked to QoL (Shiells et
al. 2019). These themes were activities, maintaining previous roles,
reminiscence, freedom and choice, appropriate environment, meaningful
relationships, support for grief and end-of-life care.
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2.5 SUMMARY OF THE LITERATURE
Neuropsychiatric symptoms are among the most complex, stressful, and costly
aspects of dementia care. They have been shown to lead to higher morbidity
and mortality rates, hospital stays, and early placement in long-term care
(Wancata et al 2003, Kales et al. 2005, Mar et al. 2019).
The use of psychotropic drugs is common in people with dementia, especially
those in long-term care. They are mainly used to manage NPSs, although their
efficacy and balance of harms and benefits remains uncertain. The amount of
evidence on the harms of psychotropic drugs, including falls, has increased in
recent years. We lack information on whether or not this has changed
prescribing among older adults with dementia in long-term care. Longitudinal
studies can offer important information on how the use of these types of
medication has changed over time. Systematic assessment of adverse effects is
also essential in order to improve the care of older adults with dementia.
Factors behind falls have been extensively studied, and it is well known that
people with dementia have a higher risk of falling (Tinetti et al. 1988,
Fernando et al. 2017). Individual risk factors of falls are multiple and vary
between community- and institution-dwelling older adults with cognitive
impairment (Allan et al. 2009, Kröpelin et al. 2012, Fernando et al. 2017).
There is evidence that the use of psychotropic drugs increases fall risk. The
results of some studies have also suggested that NPSs predict falls (Hasegawa
et al. 2010, Suzuki et al 2012, Sylliaas et al. 2012). What has not been
established yet is the interplay of NPSs and psychotropics and the relationship
between NPSs and falls.
Neuropsychiatric symptoms are known to affect the quality of life of both the
patient and the caregiver. What remains unclear are the factors that explain
this association and whether or not these factors are different in frail older
adults in later stages of dementia.
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In summary, the relationships between NPSs and falls, psychotropic drug use
and quality of life in dementia are complex. There is continuous interplay
between the different factors (Figure 4). Gaps in the current literature justify
a more detailed study looking at the factors modifying these relationships.
Figure 4. Interplay between neuropsychiatric symptoms, medication, falls,
and quality of life among older adults with dementia
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AIMS OF THE STUDY
The aim of this study was to examine the relationships between NPSs, falls,
psychotropic drug use, and HRQoL among people with dementia. Specific
research questions in the individual studies were as follows:
1. What is the relationship between NPSs and falls in older people with
cognitive impairment? (Studies I and IV)
2. Does long-term exercise intervention modify the risk of falling
associated with NPSs in community-dwelling people with AD? (Study
I)
3. Do psychotropic drugs modify the relationship between NPSs and falls
among older people with cognitive impairment in long-term care?
4. What are the trends in prevalence of use of psychotropic medication and
opioids according to residents’ dementia status in institutionalized
older adults in Helsinki over a 14-year period? (Study II)
5. What is the association between NPSs and HRQoL, and, further, does
the severity of dementia modify this relationship? (Study III)
63
METHODS
4.1 PARTICIPANTS
4.1.1 STUDY I
The drug reimbursement register of the Social Insurance Institution of
Finland was used to recruit community-dwelling people with AD living in the
cities of Helsinki, Vantaa, and Espoo to an exercise trial in 2008. For an
individual to be included in this register, a neurologist or a geriatrician has
diagnosed him or her with AD based on NINCDS-ARDRA criteria (McKhann
et al. 2011). A letter offering the possibility of participating in the trial was
mailed to all 1,264 of these individuals. Those who expressed an interest in
participating (n = 497) received a postal questionnaire asking for information
on inclusion criteria: established AD, aged 65 and older, living with a spouse
at home, no diagnosed terminal disease, and walking independently with or
without a mobility aid. Participants were also required to have at least one of
the following signs of frailty: one or more falls in the past year, a decrease in
walking speed, and unintentional weight loss. After receiving the completed
questionnaire, the study nurse conducted a telephone interview with the
spousal caregiver to ensure that all inclusion criteria were met. Two hundred
ten participants met the inclusion criteria and were enrolled in the study
(Figure 5). In a sub-study, we included all participants (n = 179) with at least
three months of follow-up and whose spousal caregiver had completed the
Neuropsychiatric Inventory (NPI).
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Figure 5. Flow chart of Study I.
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4.1.2 STUDY II
In this study data from four cross-sectional studies exploring medication use
and nutrition in institutional settings in Helsinki were combined. The studies
were conducted among all NH residents of Helsinki in 2003 (n=1987), 2011
(n=1576), and 2017 (n=791), and among all assisted-living facility (ALF)
residents of Helsinki in 2007 (n=1377), 2011 (n=1586), and 2017 (n=1752).
The 2003, 2011, and 2017 samples comprised 94%, 81%, and 68% of the total
NH population, and the 2007, 2011, and 2017 samples 66%, 64%, and 64% of
the total ALF population, respectively. The nonparticipants were those having
moderate-severe dementia (CDR 2-3) with no close proxy to give informed
consent, those who refused to take part, and those who did not provide a
complete medication list (Figure 6).
In Finland, ALFs provide round-the-clock care, with a registered nurse in
charge. This is similar to the care provided in NHs, but ALFs are designed to
resemble residents’ own home environment to a greater extent. ALFs include
both apartments and group homes for people with dementia. However, the
number of registered nurses is lower in ALFs than in traditional NHs. As a
result of organizational change of long-term care in Helsinki the number of
NH beds in Helsinki significantly declined from 2003 to 2017, and this has
been compensated for by an increase in the number of ALF beds. The national
recommendation for minimum staffing levels in 24-hour care is 0.6 employees
per resident in NHs and 0.5 in ALFs.
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4.1.3 STUDIES III AND IV
The participants were recruited to these studies from institutional settings in
Helsinki in 2017. The study was offered to all 54 long-term-care facilities in
Helsinki including both NHs and ALFs. Of these, the first 18 to volunteer were
included. We recruited and assessed consecutive participants from each of
these facilities until we reached a targeted sample of 544. The participants’
baseline assessment occurred between February 2018 and August 2018. All
participants who completed the Neuropsychiatric Inventory (NPI) at baseline
(n=532) were included in both studies. For Study IV the participants were
followed for 12 months or until death as regards falls whichever came first
(Figure 7).
Figure 7. Flow chart of Studies III and IV
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4.2 STUDY I INTERVENTION
Before intervention, a geriatrician assessed each participant’s health status to
ensure their safety. The intervention groups exercised under the supervision
of a physiotherapist for one hour twice a week over one year in their own
homes or at the gym. The exercise sessions comprised strength, balance,
endurance, and multitask training, including training on a restorator cycle,
Nordic walking, stair climbing, picking up items from the floor, and talking
while walking. The control group received normal community care
(rehabilitation in the public healthcare system, including physiotherapy if
needed).
4.3 DATA COLLECTION
In Study I, which concerned the relationship between NPSs and falls in home-
dwelling older adults with AD, a registered nurse and a physiotherapist
assessed the participants and their spousal caregivers four times (baseline,
and at three, six and 12 months). The assessors were blinded to group
allocation.
In Study II, which concerned temporal trends in the prevalence of use of
psychotropics and opioids, and sedative load in long-term-care settings over a
14-year period in relation to the residents’ dementia status, nurses in each
long-term-care setting were trained thoroughly to collect data and perform the
assessments.
In Studies III and IV, which concerned the association between NPSs and
HRQoL and the relationship between NPSs and falls, respectively, trained
study nurses collected data and performed the assessments. The author
participated and supported the nurses in their assessments and data
collection.
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In all studies data on demographic factors (age, sex, and education),
diagnoses, and medication use were collected from medical records on the
assessment day. Only regularly used types of medication were considered.
Medication use was considered regular if there was a documented regular
sequence of administration. The Charlson Comorbidity Index was used to
calculate each resident’s burden of comorbidity (Charlson et al. 1987).
4.4 MEASURES
4.4.1 NEUROPSYCHIATRIC MEASURES
To evaluate NPSs the Neuropsychiatric Inventory (NPI) (Cummings 1997) tool
was used in Studies I, III and IV. The original NPI includes 10 common
dementia NPSs (aberrant motor behavior, agitation, anxiety, apathy,
disinhibition, delusions, dysphoria, euphoria, hallucinations, irritability). For
each symptom, the severity is multiplied by the frequency, and the sum score
provides the total NPI score (range 0 to 120). According to previous studies,
an NPI score >3 is considered to indicate the presence of clinically significant
symptoms (Schneider et al. 2001, Steinberg et al. 2004, Aalten et al. 2008). In
Studies III and IV the participants were divided into groups according to their
NPI points: no significant NPSs (NPI 0–3), low NPS burden (NPI 4–12), and
high NPS burden (NPI>12). Specific scores for four different subsyndromes,
i.e. “psychosis” (delusion, hallucinations), “hyperactivity” (agitation,
euphoria, disinhibition, irritability, aberrant motor behavior), “affective
symptoms” (depression and anxiety), and “apathy” (apathy) were also
calculated separately, as described by Aalten et al. (Aalten et al. 2008).
The Cornell depression scale was used to assess depressive symptoms
(Alexopoulos et al. 1988). The scale consists of 19 items including questions
about mood-related signs, behavioral disturbances, physical signs, cyclic
functions, and ideational disturbances. Evaluation is based on interviews of
both patient and/or nursing staff member. All items are evaluated as either
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0=absent, 1=mild or intermittent, or 2=severe. The total score ranges from 0
to 38, in which lower scores refer to no depression or mild depressive
symptoms and scores of 13 and higher refer to more severe depression
(Alexopoulos et al. 1988).
4.4.2 COGNITIVE MEASURES
Global cognition was measured by using the Mini-Mental State Examination
(MMSE) (Folstein et al. 1975) and the Clinical Dementia Rating (CDR) scale
(Hughes et al. 1982).  Each instrument has its advantages and disadvantages.
It has been suggested that the CDR score reflects actual functioning better than
the MMSE score (Juva et al. 1995).
The MMSE is an instrument widely used in clinical practice as well as in
research (Tombaugh et al. 1992) to assess the severity of cognitive impairment
and to document cognitive changes that occur over time. The MMSE was
designed to examine cognitive functions, including orientation, attention,
recall, language, ability to follow instructions, ability to produce a meaningful
written sentence, and visual construction. The maximum MMSE score is 30
points. Age, education, and cultural background affect the test results and
need to be taken into consideration when interpreting the results (Tombaugh
et al. 1992, Ylikoski et al. 1992, O'Bryant et al. 2008). In people with a
neurocognitive disorder, MMSE points 0–11  usually refer to severe dementia,
12–17 to moderate dementia, 18–23 to mild dementia, and 24–30  to MCI or
normal cognitive functioning (Memory Disorders: Current Care Guidelines,
2017).
The Clinical Dementia Rating (CDR) scale is a tool which has demonstrated
high validity and reliability (Hughes et al. 1982). It is a 5-point scale used to
characterize six domains of cognitive and functional performance applicable
to AD and related dementias. The domains include memory, orientation,
judgment & problem solving, community affairs, home & hobbies, and
personal care. Each category is marked independently. Memory is considered
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the primary category and all others are secondary. The necessary information
to make each rating is obtained through a semi-structured interview of the
patient and a reliable informant (e.g., family member or nurse). The CDR score
ranges from 0–3 (0 = Normal, 0.5 = Very Mild Dementia, 1 = Mild Dementia,
2 = Moderate Dementia, 3 = Severe Dementia) (Morris 1993).
4.4.3 FUNCTIONAL MEASURES
In Study I, functional status was evaluated by using the Functional
Independence Measure (FIM) (Pollak et al. 1996) and the Short Physical
Performance Battery (SPPB) (Guralnik et al. 1994). The FIM consists of 18
categories of which five concern cognitive functioning and 13 concern physical
functioning. Each category is rated on a scale from 1 to 7, in which 1 refers to
total assistance required and 7 refers to full independence. The total score
ranges from 18 to 126 points. The lower the score, the more likely the person
needs assistance.
In Study II, function and mobility were assessed by using the Mini Nutritional
Assessment (Guigoz et al. 2002) item on mobility and categorized as either 0=
“unable to get out of a bed, a chair, or a wheelchair without the assistance of
another person” or 1=“able to get out of bed or a chair without help.”
In Studies III and IV, function was evaluated by using the Barthel Index (BI)
(Mahoney et al. 1965). The BI covers 10 personal activities: feeding, moving
from wheelchair to bed and returning, personal toileting, getting on and off a
toilet, bathing, walking on a level surface (or propelling a wheelchair if unable
to walk), dressing and undressing, ascending and descending stairs,
controlling the bladder and controlling the bowel. Each item is rated thus:
0=unable, 5=needs help, 10=independent. The maximum BI score is 100. BI
scores of 0–20 indicate total dependency, 21–60 indicate severe dependency,
61–90 indicate moderate dependency, and 91–100 indicate slight dependency
(Shah et al. 1989).
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In Study III, frailty was also assessed. Phenotypic frailty status was defined by
using modified Fried criteria (Perttilä et al. 2017), i.e. four criteria as follows:
(1) shrinking was based on weight loss of ≥ 5% in the preceding year, (2)
physical weakness was based on self-reported or care-staff evaluation of
difficulty in carrying a bag of groceries, (3) exhaustion was based on self-
reported or care-staff evaluation of low energy during the preceding four
weeks, and (4) physical inactivity was based on the response to the question:
“Do you/does the resident exercise regularly weekly?” A negative response
meant physical inactivity. The sum of fulfilled criteria classified the person as
“not frail” (no criteria),“pre-frail” (1–2 criteria), or “frail” (3–4 criteria).
4.4.4 NUTRIONAL MEASURES
In all studies Mini Nutritional Assessment (MNA) was used to assess and
grade each participant’s nutritional status (Guigoz et al. 2002). The MNA
consists of 18 questions of which six are for screening and twelve are for
assessment. For each question the lowest score is 0 and the highest score
ranges from 1 to 3. Total points come to 0 to 30, of which points <17 indicate
malnutrition, points from 17 to 23.5 indicate risk of malnutrition, and points
from 24 to 30 indicate normal nutritional status.
4.4.5 HRQoL MEASURES
The 15D instrument was used in Study III to assess HRQoL. It is a generic 15-
dimensional measure. It has been internationally validated in various
population samples (Sintonen 2001). It correlates well with other HRQoL
measures such as SF-36 (Ware et al. 1992) and EQ-5 (Hawthorne et al. 2001).
15D includes the following 15 dimensions: mobility, vision, hearing, breathing,
sleeping, eating, speech (communication), excretion, usual activities, mental
function, discomfort and symptoms, depression, distress, vitality, and sexual
activity. Each dimension is divided into five levels. A single weighted index can
be constructed from these 15 dimensions. The single index score of 0–1
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represents overall HRQoL. The maximum score is 1 (no problems on any
dimension) and the minimum score is 0. Usually the 15D paperwork is filled
in by the subject being assessed, but it may also be filled in by the interviewer
of the subject or his/her proxy. The 15D instrument shows good discriminant
validity among various aged populations, and also prognostic validity
(Strandberg et al. 2006).
4.4.6 MEDICATION
To assess medication use, the Anatomical Therapeutic Chemical (ATC)
classification system was used in all four studies. It classifies drugs into
different categories according to their therapeutic, pharmacological, and
chemical properties, and the organ or system on which they act (WHO 2020).
ATC central-nervous-system drugs (code N) include psychotropics (N05),
which are divided further into antipsychotics (N05A), anxiolytics (N05B), and
hypnotics and sedatives (N05C). Antidepressants are classified as group
N06A. In all four studies assessment was made of the use of Alzheimer’s
medication (N06D), including cholinesterase inhibitors (N06DA) and/or
memantine (N06DX01), because they are often used in connection with NPSs,
as alternatives to psychotropics.
In Study II, pain medication use was also assessed. The drugs included in the
study were opioids (N02 A), which were further categorized as weak opioids
(codeine, buprenorphine, tramadol) and strong opioids (morphine, fentanyl,
oxycodone), as well as paracetamol (N02BE01) and nonsteroidal anti-
inflammatory drugs (NSAIDs) (M01 A). Pregabalin (N03AX16), gabapentin
(N03AX12), carbamazepine (N03AF01), oxcarbazepine (N03AF02), and
valproic acid (N03AG01) were also included in order to assess the overall use
of sedative medication.
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4.4.7 FALLS
In Study I, the participants’ spouses recorded falls during the one year of
follow-up in daily fall diaries. The number of falls was noted at each study visit.
A fall diary has been found to be the most valid method to record the number
of falls (Hannan et al. 2010)
In Study IV, records of all falls were retrieved from nurses’ daily electronic
charts over one year.
4.5 ETHICAL CONSIDERATIONS
The Ethics Committee of Helsinki University Central Hospital approved the
study protocols for all studies. All participants, and in the case of Study I their
spousal caregivers, provided written, informed consent. In cases of significant
cognitive decline (CDR 2 or 3), the spouse (Study I) or the participant’s closest
proxy (in Studies II, III and IV) gave consent.
4.6 STATISTICAL METHODS
Data are presented as means with standard deviations (SDs) or as counts with
percentages. In Study I, baseline data of the groups were compared by using
the t-test, the bootstrapped-type t-test, Wilcoxon’s rank-sum test, the Chi-
square test, or the Fisher–Freeman–Halton test, as appropriate. In Studies II–
IV statistical significance for the unadjusted hypothesis of linearity across
characteristics of the study participants were evaluated by using the Cochran–
Armitage test for trend, analysis of variance (ANOVA), or logistic (ordinal)
models, with appropriate contrast. A bootstrap method was used when the
theoretical distribution of the test statistics was unknown or in the case of
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violation of assumptions (e.g. non-normality) in Study IV. The normality of
variables was evaluated by using the Shapiro–Wilk W test.
In Studies I and IV the numbers of falls and incidence rates were calculated
assuming a Poisson distribution. Adjusted incidence rates and incidence rate
ratios (IRRs) were calculated using a Poisson regression model. In Study I the
model included gender, age, MMSE score, and SPPB totals as covariates. In
Study IV the model included gender, age, and mobility as covariates. Poisson
regression analysis was carried out using goodness-of-fit of the model, and the
assumption of overdispersion in the Poisson model was tested using the
Lagrange multiplier test. In Study IV the possible nonlinear relationship
between all the falls and the NPI total score was assessed by using a 3-knot-
restricted cubic (placed according to Harrell’s recommended percentiles)
spline Poisson regression model.
In Study II the number of types of medication was calculated using a Poisson
regression model and the proportion of opioid users was evaluated by using a
logistic model. The models included age, gender, Charlson comorbidity index,
and mobility as covariates. The bootstrap method was used when the
theoretical distribution of the test statistics was unknown, or in the case of
violation of assumptions (e.g. non-normality).
In Study III the adjusted hypothesis of linearity (orthogonal polynomial) in
the relationship between NPI and 15D scores according to CDR classes was
evaluated using analysis of co-variance (ANCOVA) adjusted for age, sex, and
the Charlson Comorbidity Index. In cases of violation of assumptions (e.g.
non-normality), a bootstrap-type test was used (5000 replications). Adjusted
(partial) correlation coefficients were calculated by Pearson’s method with
bootstrapped 95% confidence intervals.
All analyses were performed using Stata version 15.0 or 16.0 software (Stata
Corp., College Station, TX).
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RESULTS
5.1 CHARACTERISTICS OF SAMPLES
There were four large samples of older adults in this study (Table 5. Baseline
characteristics of the participants). The sample sizes ranged from 179 to 4715.
Table 5. Baseline characteristics of the participants
Variable FINALEX RCT
2008-2010
n=179
Nursing homes
2003-2017
n=4354
Assisted living
2007-2017
n=4715
Long-term care
2018-2019
n=532
Study 1 2 2 3, 4
Age, mean 78 84 84 84
Women, % (n) 38.5 (69) 78.6 (3422) 75.7 (3567) 79.7 (424)
CCI, mean 2.6 2.1 2.2 2.1
Not able to move
independently, % (n)
0 (0.0) 46.9 (2042) 22.7 (1273) 57.5 (306)
MNA, % (n)
>23.5 well nourished
17-23.5 at risk
<17 malnourished
27.4 (49)
70.9 (127)
1.7 (3)
27.1 (1180)
62.9 (2739)
9.9 (431)
16.2 (764)
63.5 (2994)
20.3 (957)
14.3 (76)
66.7 (355)
16.4 (87)
CDR, % (n)
     0.5–1 35.8 (64) 38.2 (1663) 55.4 (2612) 9.3 (49)
     2 50.8 (91) 29.1 (1267) 23.4 (1103) 27.0 (144)
     3 13.4 (24) 32.7 (1424) 21.2 (1000) 63.7 (339)
No. of regularly used
medications, mean
6.9 7.8 8.6 8.5
Taking a psychotropic
medication, % (n)
31.9 (57) 68.1 (2965) 65.6 (3093) 87.0 (463)
On cognitive
enhancers, % (n)
97.5 (175) 22.6 (984) 39.3 (1853) 43.3 (230)
CCI=Charlson Comorbidity Index (Charlson et al. 1987); MNA=Mini Nutritional Assessment
(Guigoz et al. 2002); CDR=Clinical Dementia Rating (Hughes et al. 1987). In nursing-home and
assisted-living cohorts just the CDR memory item was used. Psychotropics included antipsychotics
(N05A), antidepressants (N06A), anxiolytics (N05B), hypnotics and sedatives (N05C). Cognitive
enhancers included cholinesterase inhibitors (N06DA) and/or memantine (N06DX01).
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The mean ages ranged from 78 to 84 years. Females comprised the majority of
participants in three of the four samples. Only in the FINALEX trial were
males prominent (61.5%), due to the fact that the inclusion criteria included a
spouse living at the same address.
The participants had a high number of comorbidities (CCI range 2.1 to 2.6),
which in turn corresponds to a moderate risk of one-year mortality. All
participants in the FINALEX trial were able to move independently, as this
was one of the inclusion criteria. In the nursing-home sample in 2003–2017
about 47% were unable to move independently, and the respective figure in
assisted-living facilities in 2007–2017 was 23%. In the most recent sample
from all long-term units (in 2018–2019), almost 60% were unable to move
without help.
A risk of malnutrition was common in all samples. A majority (72.6%) of
home-dwelling AD patients were at risk of malnutrition or were malnourished.
Respective figures were 72.8% in nursing homes, 83.8% assisted-living
facilities and 83.1% in long-term-care wards.
The participants varied in the severity of cognitive impairment. Most of the
participants in the FINALEX trial had mild to moderate dementia (CDR 0.5–
2), whereas almost all long-term-care residents had moderate to severe
dementia (CDR 2–3). The participants were also given a high number of drugs;
mean range from 6.9 to 8.6. Of the participants, 32–87% were taking
psychotropics, and 23–98% cognitive enhancers.
The baseline table shows important temporal changes in the long-term-care
resident profile: both mobility disabilities and cognitive impairment are more
prevalent and more severe in the most recent sample.
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5.2 RELATIONSHIP BETWEEN NPSs AND FALLS IN
OLDER PEOPLE WITH COGNITIVE IMPAIRMENT
(STUDIES I AND IV)
In both Study I and Study IV falls had a clear relationship with NPSs,
measured by the total NPI score. According to the results of Study IV,
psychotropic drug use did not modify this association. In Study I the incidence
of falls increased linearly with NPI score in the control group, whereas it stayed
at the lower level irrespective of NPI score in the intervention group.
In Study IV the NPI total score showed a curvilinear association with the
incidence rate of falls per person-year (Figure 8).
Figure 8. Incidence of falls per person-years (pyrs) according to the
Neuropsychiatric Inventory (NPI) total score. Adjusted for age, sex and
mobility.
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When comparing the three NPS groups (NPI 0–3, NPI 4–12, NPI >12), they
did not differ as regards their age, sex, or MMSE and CCI scores. However,
higher NPI points were associated with better mobility and a higher number
of types of psychotropic medication (Table 6).
In Study IV the total follow-up time was 446.8 person-years, with a mean time
of 0.84 (range 0.01–1.00) years per person. Approximately a third of the
participants died before the end of the follow-up year: 28.7% in the group with
no significant NPSs, 33.2% in the low-NPS-burden group, and 33.7% in the
high-NPS-burden group (p=0.56). However, all these participants’ falls were
recorded during their follow-up. Altogether, 606 falls occurred during the
follow-up period: 330 in the high-NPS-burden group, 188 in the low-NPS-
burden group, and 88 in the no-NPS group. Of the 606 falls, 121 led to injuries,
42 to injuries needing hospitalization and 20 to fractures.
Falls and injuries increased significantly with neuropsychiatric symptom
burden. Using the no significant NPSs group as a referent, the low-NPS-
burden group had an IRR per SD for falls of 1.64 (95% CI 1.27–2.12, adjusted
for age, sex and mobility), whereas in the high-NPS-burden group the IRR per
SD was 2.43 (95% CI 1.91–3.08, adjusted for age, sex and mobility) (p for
linearity < 0.001).
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Table 6. Characteristics of residents grouped by severity of neuropsychiatric
symptoms according to Neuropsychiatric Inventory (NPI) total score
NPI 0-3
N=167
NPI 4-12
N=181
NPI >12
N=184
P for trend
Age, mean (SD) 84 (8) 85 (7) 85 (7) 0.35
Women, n (%) 132 (79) 139 (77) 153 (83) 0.31
Charlson Comorbidity Index,
mean (SD)
2.1 (1.3) 2.2 (1.3) 2.0 (1.3) 0.28
Barthel Index, mean (SD) 21 (24) 26 (23) 33 (25) <0.001
Mobility <0.001
    Able to walk without help 44 (26) 73 (40) 109 (59)
    Able to walk only with help 55 (33) 53 (29) 52 (28)
    Bed-ridden 68 (41) 55 (30) 23 (13)
CDR,n (%) 0.35
     0.5-1 26 (16) 13 (7) 10 (5)
     2 37 (22) 51 (28) 57 (31)
     3 104 (62) 117 (65) 117 (64)
MMSE, mean (SD) 6.8 (8.6) 6.4 (7.4) 6.9 (7.6) 0.89
Number of medications,
mean (SD)
7.9 (3.6) 8.8 (3.5) 8.8 (3.8) 0.031
Number of Psychotropic
medications, mean (SD)
1.8 (1.3) 2.1 (1.5) 2.3 (1.4) <0.001
On Alzheimer medication,
n (%)
62 (37) 82 (45) 87 (48) 0.041
No major vision deficits n, % 129(77) 146(81) 153(83) 0.16
No major hearing deficits n, % 155(93) 176(97) 181(98) 0.007
NPI total, mean (SD) 0.7 (1.1) 7.9 (2.8) 28.8(14.1)
NPS subgroups, mean (SD)
        Psychosis 0.2 (0.6) 1.1 (1.9) 4.8 (6.1)
        Hyperactivity 0.3 (0.7) 4.7 (3.7) 15.6 (9.8)
        Affective 0.2 (0.6) 1.1 (1.9) 5.5 (5.7)
        Apathy 0.1 (0.4) 1.0 (2.3) 2.9 (4.0)
Charlson Comorbidity Index (Charlson et al. 1987); Barthel Index (Mahoney et al. 1965);
CDR=Clinical Dementia Rating (Hughes et al. 1987); MMSE= Mini Mental State Examination
(Folstein et al. 1975); Psychotropics included antipsychotics (N05A), antidepressants (N06A),
anxiolytics (N05B), hypnotics and sedatives (N05C); Alzheimer medication included cholinesterase
inhibitors (N06DA) and/or memantine (N06DX01); NPI= Neuropsychiatric Inventory (Cummings et
al. 1997); Neuropsychiatric symptoms subgroups (Aalten et al. 2007).
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There were differences in the associations between neuropsychiatric
subsyndromes and the IRRs of falls and fall-related negative consequences
(Figure 9). Psychosis and hyperactivity subgroups were associated with a
higher IRR of falls and injuries, whereas apathy showed a protective
association against falls but not injuries. Affective symptoms did not predict
falls nor injuries. Psychosis, hyperactivity and affective-symptom subgroups
were associated with a higher IRR of hospitalization, whereas apathy was not.
None of the subgroups predicted fractures.
Figure 9. Association between neuropsychiatric symptoms subgroups and
incidence rate ratio (IRR) of falls and fall related negative consequences per 1-
SD. Adjusted for age, sex, and mobility.
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5.3 INTERACTION EFFECT OF EXERCISE
INTERVENTION ON THE RISK OF FALLING
ASSOCIATED WITH NPSs IN COMMUNITY-
DWELLING OLDER ADULTS WITH AD (STUDY I)
In the FINALEX study the intervention and control groups did not differ in
their characteristics at baseline. Whereas the incidence of falls increased
linearly with NPI score in the control group in Study I, the exercise-
intervention group showed no such relationship. The fall rate was 1.48 (95%
CI 1.26–1.73) per person-year in the intervention group compared with 2.87
in the control group (Figure 10). Adjusted for age, sex, MMSE score, and SPPB
score, the IRR was 0.48 (95% CI 0.39–0.60, p < 0.001) for the intervention
group compared with the control group. Fall rates were significant in
connection with group (p < 0.001) and NPI total score (p < 0.02); the
interaction effect was also significant (p = 0.009, adjusted for sex, age, MMSE
score, SPPB score, and psychotropic medication use).
Figure 10. Incidence rate of falls in the exercise-intervention and control
groups according to Neuropsychiatric Inventory (NPI) score.
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5.4 TRENDS IN PREVALENCE OF PSYCHOTROPIC
MEDICATION, OPIOIDS, AND OTHER SEDATIVES
ACCORDING TO RESIDENTS’ DEMENTIA STATUS
(STUDY II)
Study II concerned 14-year trends in the prevalence of medication types
commonly used for the treatment of NPSs in long-term care in Helsinki. Both
in NHs and in ALFs the proportion of those with dementia and those unable
to move independently increased over the years. In both settings the mean
number of regularly used types of medication increased over the years (see
Tables 1 and 2 in Article II). The prevalence of psychotropic medication use
declined significantly in the NHs (p <0.001), whereas in ALFs there was no
linear trend (p=0.15). The prevalence of regular psychotropic medication use
in NHs fell from 81.3% in 2003 to 60.9% in 2017. In ALFs, the prevalence
remained more stable; 64.6% in 2007 and 63.6% in 2017.
Figure 11. Medication trends in Nursing Homes in 2003, 2011, and 2017.
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In NHs, the use of antipsychotic medication dropped from 42.7% to 32.7%,
whereas in ALFs the use of antipsychotic medication increased from 27.3% to
34.0%. Also, the use of antidepressants dropped from 44.9% to 32.7% in NHs.
In ALFs, the prevalence of antidepressants increased from 39.3% in 2007 to
46.3% in 2011 and dropped again to 37.5% in 2017. The prevalence of
anxiolytic use dropped from 40.9% to 14.4% in NHs and in ALFs from 24.1%
to 9.6%. The use of hypnotics also decreased significantly in NHs, from 11.3%
to 6.1%, whereas in ALFs there was a significant increase from 10.2% to 17.2%
(Figures 11 and 12).
Figure 12. Medication trends in Assisted-Living Facilities in 2007, 2011, and
2017.
The prevalence of regular opioid use increased linearly in both NHs and ALFs
over the years (p < 0.001). In NHs, the prevalence of regular opioid use
increased from 11.7% in 2003 to 30.2% in 2017. In ALFs, the increase was from
8.6% in 2007 to 21.6% in 2017. The largest increase in prevalence was
observed in strong opioids in NHs, where the prevalence increased from 1.9%
to 14.9% (Figures 11 and 12).
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When psychotropic drug users were stratified according to diagnosis of
dementia, in NHs both people with and without dementia showed a significant
decrease in the prevalence of psychotropic use over the 14-year follow-up
period (p < 0.001 for cohort), whereas people with dementia used fewer
psychotropics (p < 0.001 for dementia), and among these the use decreased
more rapidly (p < 0.001 for interaction). There was no similar interaction in
ALFs (p < 0.001 for cohort, p=0.004 for dementia, p=0.41 for interaction)
(Figure 13).
Figure 13.  Mean number of psychotropics used by NH and ALF residents
with and without dementia from 2003 to 2017.
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When opioid users in NHs were stratified according to diagnosis of dementia,
the entire cohort showed a significant increase in the use of opioids over the
14-year period (p < 0.001 for cohort). People with dementia used fewer opioids
(p < 0.001 for dementia), and the use increased more rapidly among them
compared with those without dementia (p < 0.001 for interaction). In ALFs,
the residents with dementia used fewer opioids, but the use increased over
time; there was, however, no interaction (p < 0.001 for cohort, p < 0.001 for
dementia, p=0.65 for interaction) (Figure 14).
Figure 14. The percentage of opioid users among NH and ALF residents with
and without dementia from 2003 to 2017.
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5.5 ASSOCIATIONS BETWEEN NPSs, DEMENTIA AND
HRQoL (STUDY III)
Study III concerned the association between NPSs and HRQoL, and, further,
how the severity of dementia modifies this relationship. Residents were
divided into three groups according to their NPSs (no significant NPSs (NPI
scores 0–3), low NPS burden (NPI 4–12), and high NPS burden (NPI > 12).
The groups did not differ in their stage of dementia, MMSE and MNA scores,
frailty or use of psychotropics. However, the high-NPS-burden group had the
best mean BI score and represented the largest proportion of people using
anticholinergic drugs. (See Table 1 in Article III).
Residents with severe dementia and with higher NPI scores had better HRQoL
according to 15D data than respective residents with lower NPI scores.
Residents with severe dementia (CDR 3) had worse HRQoL than residents
with mild–moderate dementia (CDR < 3). In addition, there was a significant
interaction between NPI scores and CDR (p = 0.037 for NPI, p < 0.001 for
CDR, p < 0.001 for interaction adjusted for age, sex, and Charlson
Comorbidity Index) (Figure 15).
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Figure 15. Relationship between total Neuropsychiatric Inventory (NPI)
score and Health-Related Quality of Life (15D score) in two CDR according to
Clinical Dementia rating (CDR)
HRQoL was worst for residents with severe dementia and a low NPI total score
(0–3) and best for residents with mild–moderate dementia and a low NPI
score (0–3).
In residents with severe dementia, HRQoL correlated positively with all NPS
subgroups. Thus, the higher the HRQoL, the more NPSs in each subgroup. In
residents with mild–moderate dementia, HRQoL was not significantly
correlated with any of the NPS subgroups (Figure 16).
In severe dementia, higher NPI scores correlated positively with functional
dimensions of the 15D instrument (mobility, usual activities, eating, speech,
excretion and mental function), as well as vitality, whereas in mild–moderate
dementia lower NPI scores correlated with lower levels of distress and
depression as well as vitality (Figure 17).
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Figure 16. Partial correlation between health-related quality of life (HRQoL)
(15D) and Neuropsychiatric Inventory (NPI) subsyndromes according to
clinical dementia rating (CDR). Correlation adjusted for age, sex, and the
Charlson Comorbidity Index.
Figure 17. Partial correlation between total Neuropsychiatric Inventory
(NPI) score and dimensions of 15D according to clinical dementia rating
(CDR). Correlation adjusted for age, sex, and the Charlson Comorbidity Index.
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DISCUSSION
6.1 MAIN FINDINGS
The present study concerned the relationships between NPSs, falls,
psychotropic medication use and HRQoL in older adults with dementia.
Results from both Study I and Study IV showed that NPSs and their severity
are associated with fall risk. According to Study IV, psychotropic drug use does
not modify this association. In Study I a long-term exercise intervention
program reduced the risk of falling related to NPSs in individuals with AD. The
risk of falling increased linearly with NPI score in the control group, but
exercise eliminated this risk in the intervention group.
Study II showed significant trends in the use of psychotropic medication and
opioids over the past 14 years in long-term care in Helsinki. The prevalence of
psychotropic medication decreased significantly in NHs, but not in ALFs.
There was a considerable increase in the prevalence of opioids in both settings
over time. Surprisingly, residents with dementia used fewer psychotropics and
opioids and had a lower sedative load than residents without dementia. The
study also showed important changes in resident profile. Both dementia and
mobility disabilities were more prevalent and more severe in latter cohorts and
the difference between these two settings diminished over time.
Study III showed that the severity of NPSs and the severity of dementia are
both significant factors determining HRQoL and there is significant
interaction between the two factors. A higher total NPI score was associated
with better HRQoL in residents with severe dementia, whereas among those
residents with mild–moderate dementia this association was not seen.
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6.2 INTERPRETATION OF THE RESULTS
The results of Studies I and IV concerning the association between NPSs and
falls are in line with those of the few previous studies (Hasegawa et al. 2010,
Suzuki et al 2012, Sylliaas et al. 2012, Galik et al. 2018, Sato et al. 2018). Our
results strengthen the existing evidence that NPSs are independent risk factors
of falls. According to Study IV, the fall risk related to NPSs in long-term-care
residents seems to particularly arise from hyperactivity and psychotic
symptoms. This is in line with the findings of Suzuki et al., who noted that
paranoid and delusional ideation, activity and affective disturbances, anxieties
and phobias, and total NPI score were significantly higher among participants
who fell (Suzuki et al. 2012). A population-based study carried out in Sweden
in 2005 also showed that having hyperactive symptoms was one of the factors
most strongly associated with falls (Kallin et al. 2005). The results of earlier
studies regarding wandering are contradictory. A systematic review published
in 2013 revealed wandering to be protective against falls (Kröpelin et al. 2013),
whereas more recent studies have suggested that wandering increases the risk
of falls (Sato et al. 2018, Ali et al. 2016). In our study, affective symptoms and
apathy were not associated with an increased fall risk. This could be a result of
less day-time activity, offering fewer opportunities for falling.
In accordance with the results of earlier studies, NPI scores among study
participants were relatively low, the mean NPI total score being 14.7 among
home-dwelling AD patients in Study I and 12.0 among long-term-care
residents in Study IV. This is consistent with the results of other studies carried
out in long-term care settings (Wetzels et al. 2010, Klapwijk et al. 2016, Ballard
et al. 2018, Husebø et al. 2019), but studies of home-dwelling people with
dementia have shown higher NPI scores (Conde-Sala et al. 2016, Hongisto et
al. 2018). The FINALEX study was originally designed to improve physical
functioning, so neuropsychiatric measures were secondary endpoints of the
study. Thus, the study was not primarily designed to investigate or alleviate
NPSs and thus may suffer from a floor effect.
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Data from an earlier study showed that FINALEX exercise intervention did not
decrease NPSs measured by NPI total score (Öhman et al. 2017). Thus, the
mechanism behind the interaction of exercise, NPSs, and falls was probably
connected to the beneficial effects of exercise on muscles and balance. It was
also shown in a previous article concerning the FINALEX study that people
with advanced dementia in particular – those suffering more often from
hyperactivity, psychosis and fall risk – benefitted more from exercise
compared with those with mild dementia (Öhman et al. 2016). Another
potential mechanism to consider is improvement in executive functioning as a
result of exercise intervention, as reported in an earlier study examining the
effects of exercise on cognition (Öhman et al. 2017).
The results of Study II are in line with those of other studies concerning the
growing trend of opioid use in institutional settings (La Frenais et al. 2018,
Sandvik et al. 2016). However, opioid use in Helsinki is still lower than among
disabled Medicaid beneficiaries in the US (La Frenais et al. 2018). In contrast
to the results of a previous Finnish register-based study among community-
dwelling older adults (Hamina et al. 2017), the use of opioids was lower among
people with dementia than among those without. The increased use of opioids
may reflect the global “opioid epidemic” (Humphreys 2017). On the other
hand, in end-of-life care, the use of opioids and psychotropics is often
appropriate and it has also been noted that pain assessment and management
are suboptimal among patients with dementia in long-term care (Lichtner et
al. 2014). The data from our study does not indicate the symptoms for which
the opioids were used. The changes detected in the use of medication may
partly reflect the changes in the resident profile, as both dementia and mobility
disabilities were more prevalent and more severe in latter cohorts. It is known
from Statistics Finland’s statistics on the population structure that the number
of older adults has grown significantly over the last 15 years. According to these
statistics there were 600,000 persons aged at least 70 at the end of 2003 and
874,314 persons aged at least 70 in Finland at the end of 2019 (Official
Statistics of Finland, 2019). At the same time, the proportion of older adults in
long-term care has decreased. In Helsinki in 2000 12% of people aged at least
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75 were in long-term care: 9.9% in NHs and 2.1% in ALFs, compared with 2.4%
in NHs  and  6% in ALFs in 2017 (Finnish Institute for Health and Welfare,
2019).
In Study III, surprisingly, in residents with severe dementia a higher total NPI
score was associated with better HRQoL, whereas among those residents with
mild–moderate dementia this association was not seen. In severe dementia,
better HRQoL correlated with higher points in all neuropsychiatric
subsyndromes. This result contrasts with those of most previous studies, in
which it has been shown that having NPSs impairs quality of life (Hurt et al.
2008, Wetzels et al. 2010, Klapwijk et al. 2016, Hongisto et al. 2018). There
are several explanations for this. One important thing to consider concerns the
differences between the various QoL instruments used in different studies. In
our study we used 15D. Several dimensions of 15D measure physical
functioning. In severe dementia, higher NPI scores correlated positively with
functional dimensions of 15D (mobility, usual activities, eating, speech,
excretion, and mental function) as well as vitality, whereas in mild–moderate
dementia lower NPI scores correlated with lower levels of distress and
depression as well as vitality. Another possible explanation concerns the study
population. In Study III, the cognition of the residents was relatively low, the
mean MMSE score being 6.8. Thus, one explanation for why the results differ
from those of most previous studies could to some extent be related to the
characteristics of the study population. To the best of my knowledge, only one
earlier study on quality of life in nursing-home residents (van der Zon et al.
2018) revealed a positive correlation between a higher NPI score and the
course of quality of life. In that study the cognition of the residents was also
low, the mean MMSE score being 7.1, which is similar to that in Study III.
6.3 STRENGTHS AND LIMITATIONS
Study I was a secondary analysis of the original FINALEX trial. It has several
strengths. An RCT is the gold standard for measuring the effectiveness of an
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intervention. Although no study is likely on its own to prove causality,
randomization reduces bias and provides a rigorous tool to examine cause-
effect relationships between an intervention and outcome. Although the
current study combined two intervention groups and was not an intention-to-
treat analysis, the comparison groups were similar at baseline. In the
FINALEX trial every participant had a confirmed diagnosis of AD. The exercise
interventions were simple and clearly described. Adherence to the
intervention was high, and the outcome measures were valid (Pitkälä et al.
2013). The participants’ spouses recorded falls in daily fall diaries, which is a
method that is highly sensitive in accurate recording of falls (Hannan et al.
2010).
The study also has some limitations that should be considered when
interpreting the results. All participants were community-dwelling Caucasians
living with their spousal caregivers. Because older couples were recruited, and
men are more likely to have a surviving spouse, two-thirds of the participants
with AD were men. Some limitations in external validity may also exist, as the
participants were motivated volunteers living in their own homes in an urban
area.  Generalizing these results to other groups of individuals with AD should
be carried out with caution. Nevertheless, there is no study that is completely
representative of a population, and the baseline characteristics were similar to
those in previous studies of people with dementia, supporting the
generalizability of the results in this group. As mentioned above, this was a
secondary analysis of the original trial. Neuropsychiatric measures were
secondary endpoints of the study, so NPS scores were low at baseline. An
additional limitation is that the FINALEX study was not double-blinded, thus
exposing the study to a risk of bias. However, the outcome assessors were
blinded to group allocation and they were unaware of the precise study
question. Use of psychotropic medication can be a possible confounder as
regards falls and thus the analysis was adjusted for psychotropic drug use.
In Study II the major strengths are the large sample size and comparable data
collection at each of the four time points. Residents were assessed by well-
trained nurses familiar with the residents in 2003, 2007, 2011, and 2017, and
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they used the same data-collection instruments and methodology, resulting in
high validity of the data. Another strength of the study is that medication use
was taken directly from each resident’s medication administration chart,
ensuring that only the medication actually taken was included in the analysis.
Medication was classified with ATC codes, an international classification
system that allows comparison (WHO 2020). Moreover, we only considered
medication that was taken regularly. However, it has been shown that
psychotropic medication may also be administered as needed on a pro re nata
basis, so our results might underestimate the actual use of these types of
medication (Allers et al. 2017). Including psychotropics administered only on
request may have led to different results.
In Study II we were not able to follow the same resident at different time points
because the mean time spent in long-term care in Helsinki is less than two
years. Another limitation is that response rates have significantly decreased
over the years in NHs. Non-responders are mainly people with moderate–
severe dementia and no proxy. Thus, estimates of increases in dementia and
disability are probably underestimates. In addition, the organization of long-
term care in Helsinki has changed over time, challenging the comparability of
NHs. The number of NH beds has significantly decreased, whereas the
increasing number of beds in ALFs has replaced them. However, all available
residents living in long-term care in Helsinki were included.
In Studies III and IV important strengths are the relatively large
representative sample and the use of well-validated measures. Long-term-care
residents were assessed by trained study nurses, increasing the reliability of
the results. Eighteen of the 54 nursing homes in Helsinki were included.
Limitations of Study III include the cross-sectional nature of the study, which
allows us only to refer to associations within the study population but not to
draw conclusions of causality, as epidemiological cohort studies can only
demonstrate associations. Care-staff rating of residents’ HRQoL may also be
considered a limitation. However, this method was deliberately chosen
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because of the high prevalence of severe dementia, which could have
compromised the residents’ self-reporting. 15D can also be rated by a proxy
(Sintonen 2001).  It is known from previous research that there are differences
between proxy- and self-rated quality of life (Hurt et al. 2008, Beerens et al.
2013). Residents tend to consider their quality of life as being greater than do
caregivers. Assessments of residents were performed by the member of staff
who knew each particular resident best, in order to increase the validity of the
data. The study population was made up of long-term-care residents with
advanced dementia and, therefore, the results cannot be generalized to other
populations with dementia. Even though the CDR scale is one of the most well-
known and well-studied dementia-staging instruments, it is, however, not
without limitations. A CDR score addresses both cognition and physical
functioning, but it may also be influenced by physical comorbidities (Juva et
al. 1995). Another limitation is that pain and use of physical restraint, possible
confounders, were not assessed in our studies. It is well known that despite
clear evidence of a lack of effectiveness and safety, physical restraints are
frequently used in nursing homes and their use is associated with falls (Foebel
et al. 2016, Lam et al. 2017). Another limitation is that only regularly used
psychotropic medication was considered in our study. Psychotropics
administered as needed on a pro re nata basis may have had a different impact
on falls and their consequences.
Study IV, as a longitudinal follow-up study of a special cohort, is less
susceptible to selection bias, because the cause always precedes the outcome
(Hartung et al. 2009). However, we cannot rule out of confounders affecting
both NPSs and falls. A major challenge, though, is patient follow-up. Loss of
follow-up within a cohort can be a major source of selection bias, because
participants who drop out do so for a reason that is unlikely to be random. In
Study IV approximately a third of the participants died before the end of the
follow-up year: 28.7% in the group with no significant NPSs, 33.2% in the low-
NPS-burden group, and 33.7% in the high-NPS-burden group (p=0.56).
However, all these participants’ falls were also recorded during their follow-
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up. However, we cannot rule out unknown confounders having an effect on the
results.
In Studies I, III and IV only the NPI was used to assess NPSs. Thus, no efforts
were made to rule out delirium, which might be common in this population. It
has been shown in a previous study that NPSs and delirium overlap (Hölttä et
al. 2011). Delirium is a major risk factor of falls (Sillner et al. 2019).
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CONCLUSIONS
Neuropsychiatric symptoms and their severity are associated with fall
risk among people with dementia – both among home-dwelling people
and residents living in long-term care. Evaluation of NPSs, especially
their severity, and neuropsychiatric subsyndromes should be part of
comprehensive assessment when aiming to prevent falls in long-term-
care residents with cognitive impairment. Use of psychotropic drugs did
not modify the relationship between NPSs and falls among older people
with cognitive impairment in long-term care.
Exercise has the potential to reduce the risk of falls associated with
NPSs in dementia. Long-term and frequent exercise significantly
decreased the number of falls.
The prevalence of psychotropic drug use has decreased over the last 14
years in NHs in Helsinki, but at the same time the rates of opioid use
have increased in both NHs and ALFs, leading to a high overall sedative
load among long-term-care residents.
Levels of severity of both neuropsychiatric symptoms and dementia are
important determining factors of health-related quality of life. NPSs
have a distinct impact on HRQoL at different stages of dementia.
Whereas all neuropsychiatric subsyndromes (psychosis, hyperactivity,
affective, apathy) correlated positively with 15D scores in severe
dementia, no such relationship was seen in mild–moderate dementia.
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IMPLICATIONS FOR CLINICAL
PRACTICE AND FUTURE RESEARCH
The results of this study indicate that evaluation of NPSs, especially their
severity, and neuropsychiatric subsyndromes, should be part of
comprehensive assessment when aiming to prevent falls in long-term-care
residents with cognitive impairment.
Regular exercise should be promoted as part of good-quality dementia care, as
exercise has the potential to reduce the risk of falls associated with NPSs in
dementia.
All sedative drugs including opioids should be evaluated when assessing the
risk of falling in older adults with dementia. Psychotropic drugs continue to be
commonly used in long-term care in Finland and the use of opioids is rising.
Long-term-care staff should be trained as regards the adverse effects of all
types of CNS medication in order to reduce various risks related to their use.
Neuropsychiatric symptoms are associated with HRQoL. Its evaluation should
be interpreted in the light of a patient’s stage of dementia, as the association
between NPSs and HRQoL is different at later stages of dementia.
Neuropsychiatric symptoms represent a still scarcely explored topic in long-
term-care settings, in which they are the most prevalent. Such settings would
be ideal when considering RCTs related to alleviation of NPSs. Outcomes
should include NPI scores, falls, QoL and caregiver stress. In addition, an RCT
exercise study, similar to FINALEX, should be repeated in long-term-care
settings, to see whether or not exercise can reduce falls in older adults with
more severe cognitive impairment.
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Further research is also needed to determine the factors explaining the
different relationships between falls and various neuropsychiatric
subsyndromes such as apathy and hyperactivity. This could be done using
activity-sensor technology, allowing the total amount of physical activity to be
measured. Activity monitors would be ideal in determining how much long-
term-care residents actually move in normal days. Repeated cross-sectional
studies in long-term-care facilities should continue and residents’ falls, NPSs
and HRQoL should be assessed in addition to nutrition, comorbidities, use of
medication and functioning.
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